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 Anti-NMDA receptor and anti-AMPA receptor (NMDAR and AMPAR) encephalitides are 
debilitating but reversible autoimmune diseases of glutamatergic synapses of the central nervous 
system. Consistent with disruption of the major excitatory neurotransmitter in the central nervous 
system, symptoms of these newly characterized diseases are severe and include psychosis, 
memory loss, confusion, seizures, and autonomic instability. Previous work has shown that 
patients produce antibodies that can be detected in serum and cerebrospinal fluid that bind to 
NMDARs or AMPARs, causing their internalization and depletion from neuronal membranes and 
synapses. The goal of my thesis was to determine the mechanisms of patient antibody-mediated 
pathology and the compensatory responses of neurons upon antibody exposure. I used 
dissociated hippocampal neurons and organotypic hippocampal slice cultures for molecular 
(immunostaining, Western blotting, and quantitative PCR) and electrophysiological (whole-cell 
and extracellular recordings) studies.   
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I found that antibodies from patients with anti-NMDAR or anti-AMPAR encephalitis 
caused internalization of their respective receptors. This internalization was stimulated by 
receptor cross-linking by patient immunoglobulins. Antibody-bound, internalized receptors 
trafficked through both recycling and lysosomal intracellular compartments. The loss of receptors 
was specific, time-dependent, reversible upon antibody removal, and did not result in neuronal 
death or structural dismantling of excitatory synapses. No acute effects on receptor function were 
detected. In response to the decreased glutamate signaling, neurons engage homeostatic 
plasticity mechanisms to maintain action potential firing rate, including down-regulating inhibitory 
synapses and increasing intrinsic excitability. Additionally, treatment with anti-AMPAR antibodies 
altered patterns of spontaneous action potential firing. Finally, a hippocampal slice culture model 
of anti-NMDAR antibody exposure was developed and validated for use in future studies.  
My work demonstrates that the hypoglutamatergic state created by anti-glutamate 
receptor antibodies leads to both direct and compensatory cellular and synaptic changes. 
Homeostatic plasticity of inhibition and intrinsic excitability opposes the declining excitatory 
synaptic transmission, but without the preservation of action potential firing pattern. Together, the 
direct and compensatory plasticity caused by patient antibodies may change the activity and thus 
the function of key brain circuits, contributing to patients’ cognitive and behavioral symptoms.  
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PREFACE 
 
Recent years have led to remarkable progress in the diagnosis and treatment of 
autoimmune diseases of the central nervous system, including poorly understood inflammatory 
encephalitides such as limbic encephalitis. Beginning in 2007, with the discovery of anti-NMDA 
receptor (NMDAR) antibodies in the cerebrospinal fluid and serum of a group of women with 
ovarian teratomas and neuropsychiatric deterioration,1 the repertoire of autoimmune 
encephalitides in which synaptic antigens are targeted has expanded to encompass anti-AMPA 
receptor (AMPAR), anti-GABAA and GABAB receptor, anti-glycine receptor, anti-metabotropic 
glutamate receptors type 1 and 5 (mGluR1 and mGluR5), anti-voltage-gated potassium channel, 
anti-LGI, and anti-CASPR2 encephalitis.2 Recognition of non-paraneoplastic cases, i.e. patients 
with no detectable tumors, and the prevalence of the disease across gender and age, has further 
enhanced our understanding of disease etiology and has contributed to more rapid diagnosis. 
While symptoms and prevalence vary among subtypes of these disorders, a common feature is 
central nervous system dysfunction caused by disruption of synaptic and neuronal function by 
autoantibodies associated with each disorder.      
My thesis is an investigation of the mechanisms of two antibody-mediated encephalitides, 
anti-NMDAR and anti-AMPAR encephalitis. These two glutamate receptors mediate the bulk of 
excitatory neurotransmission throughout the brain,3,4 and consequently their loss of function leads 
to severe illness. Anti-NMDAR encephalitis is characterized by rapid-onset psychosis, behavioral 
and personality changes, memory loss, seizures, and autonomic instability, sometimes 
progressing to coma and death if left untreated.5 Patients with anti-AMPAR encephalitis exhibit 
confusion, agitation, memory loss, and seizures.6 With immunotherapy, these conditions are 
reversible in many patients, though recovery can be a prolonged process and relapses are not 
uncommon.7  
Chapter 1 introduces several types of autoimmune-mediated encephalitides of the central 
as well as peripheral nervous system. The known mechanisms of pathogenesis among the 
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described disorders are compared and contrasted. Finally, a number of outstanding questions 
about anti-NMDAR and anti-AMPAR encephalitis are posed.    
Chapter 2 describes the discovery of several novel features of antibody-mediated 
NMDAR dysfunction. First, patient antibodies are likely to cause a loss of function of NMDARs on 
all neurons across most brain areas. Both excitatory and inhibitory neurons are susceptible to 
antibody-induced receptor loss, and staining of rodent brain sections demonstrates antibody 
binding throughout multiple regions, indistinguishable from that of commercially available NMDAR 
antibodies directed against GluN1, the obligate NMDAR subunit of the central nervous system. 
Second, patient antibodies cause a rapid but saturable decrease in receptor levels. This 
loss of surface receptors is paralleled by an increase in the density of internalized receptors, 
more of which colocalize with markers of recycling endosomes than with lysosomes. Interestingly, 
this pattern of intracellular accumulation is not unique to this pathological event. Stimulation with 
NMDA and glycine, and treatment with picrotoxin, both lead to NMDAR internalization into these 
compartments in similar proportions.  
Third, cross-linking of receptors by patient immunoglobulin is the prominent mechanism 
of internalization, and several experiments suggest that this internalization is the likely cause of 
NMDAR hypofunction. Patient antibodies do not acutely antagonize receptor function. Neither can 
antibodies activate the receptor, which could lead to a homeostatically-driven internalization 
process; electrophysiological recordings show no acute potentiation of currents, and 
internalization is not dependent on receptor activity. 
Finally, patient antibody treatment leads to a compensatory decrease of inhibitory 
synapse density onto excitatory neurons, likely to maintain proper excitatory-inhibitory balance in 
the face of lowered glutamatergic drive.  
 In Chapter 3, the cellular and synaptic mechanisms of antibodies from patients with anti-
AMPAR encephalitis are delineated. First, patient antibodies lead to a selective loss of AMPARs 
and resulting synaptic currents from excitatory synapses, and following internalization most of 
these AMPARs are degraded in lysosomes.  
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 Second, commercial antibodies directed against extracellular epitopes do not effectively 
cause the internalization of AMPARs that is seen with patient antibodies. One commercial 
antibody, if further cross-linked with a secondary antibody, can induce a similar degree of 
internalization. 
 Finally, loss of AMPAR-mediated glutamate transmission by patient antibodies induces 
two forms of homeostatic plasticity. Inhibitory synapse density onto excitatory neurons is 
decreased, and intrinsic excitability is increased. This increase in excitability allows neurons to 
maintain their normal spontaneous firing frequency even in the face of reduced excitatory 
synaptic input, although the pattern of firing is altered. 
 Chapter 4 explores patient antibody effects on intrinsic excitability. This form of 
homeostatic plasticity is also detectable after treatment with anti-NMDAR antibodies, though 
distinct changes in passive membrane properties underlie the change after AMPAR versus 
NMDAR hypofunction. Second, a new model system for continuing our studies of these 
encephalitides, organotypic hippocampal slice cultures, is established and the same effects of 
patient antibody seen in dissociated neuronal cultures are verified in this more intact system. As 
mechanistic understanding of the effects of autoantibodies on receptors deepens, and 
subsequent homeostatic processes are uncovered, acute slices and slice cultures will allow for 
circuit-level changes mediated by autoantibodies to be linked to cognitive and behavioral 
symptoms.  
For years, neuroscientists have studied glutamate signaling in the non-human 
mammalian brain in an attempt to uncover the link between neuronal function and complex 
behavior. Manipulations of NMDARs and AMPARs are especially prominent in the literature, and 
the drive to understand the role of these receptors in behavior is further fueled by the number of 
neuropsychiatric disorders caused by or linked to mutations in genes that govern excitatory 
synapse formation and function. The discovery of a reversible human disease in which 
glutamatergic dysfunction causes cognitive and neurological impairments, therefore, becomes an 
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important avenue of inquiry, both for improving treatment and recovery for a growing population 
of patients, and for contributing to efforts to uncover the biological basis of behavior.  
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Abstract 
Recently, several novel, potentially lethal and treatment-responsive syndromes that affect 
hippocampal and cortical function have been shown to be associated with auto-antibodies against 
synaptic antigens, notably glutamate or GABAB receptors. Patients with these auto-antibodies, 
sometimes associated with teratomas and other neoplasms, present with psychiatric symptoms, 
seizures, memory deficits and decreased levels of consciousness. These symptoms often 
improve dramatically after immunotherapy or tumor resection. Here we review studies of the 
cellular and synaptic effects of these antibodies in hippocampal neurons in vitro and preliminary 
work in rodent models. Our work suggests that patient antibodies lead to rapid and reversible 
removal of neurotransmitter receptors from synapses, leading to changes in synaptic and circuit 
function that in turn are likely to lead to behavioral deficits. We also discuss several of the many 
questions raised by these and related disorders. Determining the mechanisms underlying these 
novel anti-neurotransmitter receptor encephalopathies will provide insights into the cellular and 
synaptic bases of the memory and cognitive deficits that are hallmarks of these disorders, and 
potentially suggest avenues for therapeutic intervention. 
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Introduction 
Many encephalitides once considered idiopathic are now thought to be immune-
mediated. One such disorder predominantly affects structures of the limbic system, including 
medial temporal lobes, amygdala, hippocampus, and orbitofrontal cortex.1-3 As a result, patients 
develop short-term memory deficits, emotional and behavioral disturbances such as confusion, 
irritability, depression, and sleep disturbances, as well as seizures and sometimes dementia.2,4 
For many years, limbic encephalitis was invariably attributed to the paraneoplastic manifestation 
of cancers that express the target neuronal antigen, and the neurological deficits were considered 
to be refractory to treatments. These views have changed with the discovery of an expanding 
group of encephalitides that occur with or without cancer association, respond to immunotherapy 
and range from focal limbic dysfunction to a multi-focal or diffuse encephalopathy. In contrast to 
classical paraneoplastic encephalitides in which the target antigens are intracellular and appear 
to be mediated by cytotoxic T-cell mechanisms, the novel group of disorders is associated with 
autoantigens that are on the cell or synaptic surface and appear to be directly mediated by 
antibodies.  
The pathogenic role of antibodies can be established using several criteria in vitro and in 
vivo. (i) If antigens are membrane proteins, antibodies should have access to and bind 
extracellular antigenic epitopes in living cells and ⁄ or tissues. (ii) That antibodies recognize a 
particular antigen should be assessed by expressing the antigen in heterologous cells, assayed 
by immunostaining or immunoprecipitation followed by Western blotting. (iii) Antibodies cause 
structural and ⁄ or functional alterations of the target antigen that can be established in vitro in 
dissociated neuron cultures as well as in vivo after antibody infusion. Adjuncts to these 
approaches would include using affinity-purified antibody to recapitulate the effects of human 
cerebrospinal fluid (CSF) or serum, as well as demonstrating that CSF or serum depleted of the 
particular antibody has no structural or functional effects on cells. In the particular case of 
antibodies against neurotransmitter receptors or ion channels, receptor ⁄ channel function may be 
acutely or chronically altered by antibody treatment, leading secondarily to changes in cellular 
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and ⁄ or synaptic function. (iv) The clinical syndrome should mirror some or all of the phenotypes 
of pharmacological or genetic manipulation of the antigen. (v) Passive transfer of disease-specific 
antibodies to animals should reproduce the effects of the antibodies on the antigen as well as the 
clinical features of the disorder. (vi) Cellular and synaptic alterations, and clinical symptoms, 
should improve as antibody titer is reduced. For some autoimmune diseases such as myasthenia 
gravis or Lambert–Eaton syndrome, all of these criteria have been met; however, for many, only a 
subset have been confirmed (Table 1).  
Anti-neurotransmitter receptor limbic encephalitides resemble the autoimmune 
syndromes of the neuromuscular synapse (e.g. myasthenia gravis) in that they can also occur 
with or without tumor association and are probably antibody-mediated5-8 (Table 1). However, in 
autoimmune synaptic encephalitis the autoantigen is located behind the blood–brain barrier 
(BBB), requiring that the antibodies or cells producing antibodies cross this barrier in order to 
cause neurological dysfunction (Fig 1). In some disorders the patients’ CSF shows lymphocytic 
pleocytosis and intrathecal synthesis of antibodies, suggesting that after initial systemic immune 
activation by a tumor or unknown causes, there is an expansion of the immune response within 
the nervous system.9 The role of the immune response in the neurological symptoms is further 
supported by the correlation between antibody titers and symptoms, and the frequent response of 
the disorders to immunotherapies, including plasmapheresis, intravenous Ig, corticosteroids, 
cyclophosphamide or rituximab (a monoclonal antibody that depletes B-cells).  
The importance of these disorders is that they offer human models of brain–immune 
interactions in which the target antigens have critical roles in neuronal synaptic transmission and 
plasticity. Therefore, their study will improve our understanding of the effects of the antibodies at 
the cellular, synaptic and circuit levels, eventually impacting the clinical management of the 
patients. Here we describe the three most recently identified autoimmune synaptic encephalitides 
and the state of our understanding of the cellular and synaptic mechanisms, and discuss some of 
the many questions raised by these diseases. 
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Anti-NMDA receptor encephalitis 
A new, severe, potentially lethal, treatment-responsive disorder, anti-NMDA receptor 
encephalitis, was reported recently.10,11 Patients are usually young women, but also include men, 
without a past medical history of interest, who, often after prodromal symptoms of mild 
hyperthermia, headache or a viral-like process, develop sudden behavioral and personality 
changes for which they are often seen by psychiatrists.10,11 This clinical presentation is usually 
followed by seizures, a decreased level of consciousness, abnormal movements (orofacial and 
limb dyskinesias, dystonia, choreoathetosis), autonomic instability (fluctuating blood pressure, 
cardiac rhythms and temperature) and sometimes hypoventilation. Magnetic resonance imaging 
(MRI) is frequently normal, but in about 40% of patients inflammation is transiently identified in 
hippocampus, cerebral or cerebellar cortex, and subcortical regions.12-16 Patients have serum and 
CSF antibodies that react with brain antigens predominantly expressed in the hippocampus.12 In 
two large cohorts comprising 181 patients, including young adults and children, neurologic 
improvement was correlated with a decrease in antibody titer.12,17 Overall, about 75% of the 
patients had dramatic or substantial recoveries despite the severity or long duration of symptoms; 
19% had partial or limited improvement and 6% died. Analyses of brain biopsies in 14 cases and 
autopsy of three patients showed microgliosis, occasional inflammatory B-cell and plasma cell 
infiltrates, and very rare T-cell infiltrates, in contrast to other paraneoplastic syndromes in which 
cytotoxic T-cell infiltrates are prominent.18 In the autopsy studies the most prominent microglial 
activation was localized in the hippocampus. Most patients with this disorder were previously 
categorized as ‘encephalitis of unknown etiology’.14,19 It is likely that many patients died without a 
diagnosis or recovered with empiric treatment with immunotherapy. In fact, the little autopsy 
material that is available for analysis comes from cases diagnosed retrospectively using archived 
tissue, serum or CSF. The current mortality rate of anti-NMDA receptor encephalitis is 
approximately 3%, usually as a result of complications during the stage that patients require 
intensive care and ventilatory support.12,14,17 
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 When patient antibodies are used to stain rodent brain sections, immunoreactivity is 
observed in the neuropil of the hippocampus, with less staining in cortex, striatum and 
cerebellum.12 When used to stain live cultured hippocampal neurons, patient antibodies react with 
surface antigens localized to synapses. Additional studies, including immunoprecipitation followed 
by mass spectroscopy, led to the identification of the NR1 subunit of the NMDA receptor as the 
target autoantigen. NMDA receptors are usually formed from heteromers of two NR1 and two 
NR2 subunits.20,21 There are four NR2 subunits (NR2A–D), which have 50–70% sequence 
identity in the extracellular domain; NR1 is ubiquitously distributed in the brain.22-24 Domain 
swapping and other experiments showed that the epitope was located at the N-terminal 
extracellular domain of NR1.12,25 As NR1 is ubiquitously expressed in brain as an obligate subunit 
of functional NMDA receptors,22-24 it remains unclear why patient NR1 antibodies preferentially 
label hippocampus rather than all brain regions. This binding pattern may reflect the relatively 
high density of NMDA receptors in the hippocampus or a differential post-translational 
modification of NR1 in different brain regions.25 
 We have recently shown that patients’ antibodies cause a selective, titer-dependent 
decrease of NMDA receptor surface density, synaptic localization and currents in vitro, via 
antibody-mediated capping and internalization26 (Fig 2), while overall cellular structure and 
synaptic density are largely unchanged. Moreover, these effects are reversible: after 3 days of 
treatment with patients’ CSF, followed by 4 days of treatment with control CSF, NMDA receptor 
cluster density and synaptic localization recover to levels seen in control cultures. In addition, 
NMDA receptor density is dramatically reduced in the hippocampus of rats infused with patients’ 
antibodies and in the hippocampus of autopsied patients.26 These studies demonstrated that 
patients’ NR1 antibodies reversibly alter the number and distribution of glutamate receptors in 
neurons, resulting in a decrease in glutamatergic synaptic function. The lack of neuronal death 
and the reversibility of the effects of antibodies on cultured neurons may explain, in part, the 
frequent recovery of patients with this disorder. It is unclear, however, whether the prolonged time 
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of recovery (usually several months) represents persistence of the immune response in the brain, 
slow recovery of circuit dysfunction caused by the decrease of synaptic NMDA receptors, or both. 
 
Other autoimmune synaptic encephalitides 
A goal of ongoing work in our laboratory is to determine whether other syndromes may 
involve antibodies to other surface or synaptic antigens. Currently, approximately 90% of patients 
with limbic encephalitis of non-viral etiology that we have studied have well-defined immune 
responses against neuronal antigens.27-29 The importance of antibodies to cell surface or synaptic 
proteins was shown in a recent study in which these antibodies were found to be more prevalent 
than antibodies to intracellular antigens described in paraneoplastic disorders29 (54 vs. 24%). A 
study of 1570 patients with diffuse encephalitis by the California Encephalitis Project showed that 
in only 30% could a final diagnosis be established30 (viral, bacterial, prion, parasitic, fungal). A 
pilot study examining a group of cases selected by subphenotype (‘encephalitis, psychosis and 
dyskinesias’) showed that 50% had NMDA receptor antibodies.14 This suggests that other 
antibodies to currently unknown antigens may occur in the remaining cases. A second form of 
immune-mediated encephalitis in which patients’ serum and CSF antibodies are directed against 
AMPA receptors was recently identified.31 Most patients develop a clinical picture of limbic 
encephalitis, including confusion, agitation, seizures and severe short-term memory deficits. 
Sometimes patients present with rapidly progressive abnormal behavior that resembles acute 
psychosis. Patients are usually women older than 50 years, and 70% had an underlying tumor, 
usually lung or breast cancer or tumors of the thymus that express AMPA receptors. 
Immunotherapy and treatment of the tumor, if detected, usually results in neurological recovery. 
The disorder has a tendency to relapse, and for these patients the outcome depends of how well 
each relapse is controlled. 
Staining of live cultured hippocampal neurons with patients’ serum or CSF showed that 
patient antibodies recognized cell surface antigens that were localized to synapses. 
Immunoprecipitation followed by mass spectrometry demonstrated that the target antigens were 
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the GluR1 and ⁄ or GluR2 subunits of the AMPA receptors. AMPA receptors mediate most of the 
fast excitatory synaptic transmission in the brain32 and the majority are heterotetramers 
composed of GluR1, 2, 3 or 4 subunits that are expressed in a region-specific manner.33 GluR1 ⁄ 
2 and GluR2 ⁄ 3 levels are high in hippocampus and other limbic regions,34 similar to the 
distribution of immunostaining with patients’ antibodies. Preliminary analyses suggest that the 
location of the epitope is the N-terminal extracellular domain of these AMPA receptor subunits.25 
None of these patients’ antibodies reacted with GluR3, a subunit identified as an autoantigen in 
some patients with Rasmussen’s encephalitis.35 
Treatment of rat hippocampal neurons with patients’ antibodies resulted in a significant 
decrease in the synaptic localization of AMPA receptor clusters, without a decrease in overall 
synaptic density or NMDA receptor clusters.31 Moreover, these effects were reversible: after 3 
days of treatment with patients’ CSF containing GluR1 ⁄ GluR2 antibodies, followed by 4 days of 
treatment with control CSF, AMPA receptor cluster density and synaptic localization recovered to 
levels seen in control cultures.31 
A third subtype of autoimmune encephalitis associated with antibodies against the γ-
amino-butyric acid-B (GABAB) receptor was also recently identified.36 The median age of a cohort 
of 15 patients was 62 years (range 24–75); eight were men. All presented with early and 
prominent seizures; other symptoms, as well as MRI and electroencephalography findings, were 
consistent with predominant limbic dysfunction. Forty seven percent of patients had small cell 
lung cancer, and 40% showed propensity to autoimmunity. Cancer screening and demographic 
data indicate the disorder also occurs in patients without cancer. Neurological improvement 
occurred in 60% of the patients and was correlated with prompt immunotherapy and tumor 
control. Staining of live neurons showed	  that all patients’ serum and CSF had antibodies against 
a cell surface antigen. Immunoprecipitation and mass spectroscopy demonstrated that the 
autoantigen was the B1 subunit of the GABAB receptor, a metabotropic receptor that when 
disrupted causes seizures and memory dysfunction.37,38 
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Three syndromes have been shown to be associated with antibodies against voltage- 
gated potassium channels. Neuromyotonia is a peripheral nervous system disorder characterized 
by muscle hyperactivity, while Morvan’s syndrome, in addition to peripheral muscle hyperactivity, 
has autonomic and central nervous system manifestations, including insomnia, hallucinations, 
anxiety, delirium and memory loss. The third syndrome, limbic encephalitis, consists only of 
central nervous system symptoms with no peripheral dysfunction.39 Similar to the encephalitides 
presented above, this type of limbic encephalitis can be paraneoplastic but also more frequently 
occurs in the absence of a tumor.40,41,43 Patients experience psychiatric and neurological 
symptoms including short-term memory loss, disorientation, agitation, hallucinations and 
seizures, as well as excessive secretions.40-43 In addition, voltage-gated potassium channel 
antibodies have also been reported in patients with isolated seizures and rapidly progressive 
dementia, sometimes suggesting a prion disease.41 
A number of other synaptic autoimmune disorders have been identified. These disorders 
affect neurological functions other than memory, behavior and cognition, and therefore are only 
briefly described here. Two patients with cerebellar ataxia were found to have antibodies against 
mGluR1.44 Autonomic neuropathy, a disorder affecting various autonomic nervous system 
functions, can associate with antibodies against ganglionic acetylcholine receptors.45,46 Patients 
with Miller-Fisher syndrome, a variant of Guillain-Barré causing extraocular paralysis, produce 
antibodies against ganglioside type GQ1b that cause a complement-mediated block of 
neuromuscular transmission.47 Antibodies against glycine receptors have been reported in one 
patient with progressive encephalomyelitis, rigidity and myoclonus, resulting in muscle spasms 
and rigidity, facial muscle weakness, and gaze palsies.48 Although these syndromes are of clinical 
interest, the underlying cellular mechanisms remain to be determined.  
Although in vitro approaches have been useful to establish the effects of antibodies to 
NMDA, AMPA and GABAB1 receptors on neurons and in particular on synapses, in vivo models 
will be needed to establish the relationship between the effects of each antibody on synapse and 
circuit function, and the changes in behavior, memory and cognition that are hallmarks of these 
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disorders. Below we discuss several of the many outstanding questions that, when addressed, 
will provide new insights into the basic neuroscience of synaptic plasticity as well as the clinical 
understanding of autoimmune encephalitides. 
 
Paraneoplastic and non-paraneoplastic mechanisms of autoimmune synaptic 
encephalitides 
Anti-NMDA, -AMPA and -GABAB1 receptor encephalitides are often paraneoplastic 
syndromes. In this setting, the presence of a tumor that expresses these receptors probably 
contributes to breaking immune tolerance. However, other unknown immunological triggers may 
be involved, particularly in patients without a tumor. A propensity toward autoimmunity is 
suggested by the frequent occurrence of other	  immune responses, and in the case of anti-NMDA 
receptor encephalitis, an apparent predominance in certain ethnic groups (African-American, 
Asian, Latin Americans). 14 
As in other autoimmune diseases, a number of mechanisms could potentially account for 
the immune response in the absence of a tumor. Cross-reactivity of antibodies against different 
antigens can occur if the epitopes are sufficiently similar. Guillain-Barré syndrome is an 
autoimmune peripheral neuropathy affecting axons and myelin sheaths.49,50 The disorder is 
frequently preceded by an infection, often by Campylobacter jejuni.51-53 Patients’ serum 
antibodies react with peripheral nerve gangliosides as well as lipooligosaccharide from C. 
jejuni.54-56 Other examples include Sydenham’s chorea and systemic lupus erythematosus (SLE). 
Sydenham’s chorea is characterized by abnormal movements, hypotonia and neuropsychiatric 
symptoms, and characteristically occurs after an infection by group A streptococci.57,58 Antibodies 
from these patients react with gangliosides expressed in the basal ganglia and cross-react with 
group A streptococcal N-acetyl-glucosamine.59-61 In SLE, patients with neuropsychiatric 
symptoms and sometimes asymptomatic family members harbor antibodies to double stranded 
DNA that also cross-react with a single epitope present in the extracellular region of NR2A and 
NR2B of the NMDA receptor.62,63  
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Given that most paraneoplastic disorders are triggered by small tumors at initial stages of 
the disease, it is possible that an immune response resulting in antibody synthesis decreases the 
size or eliminates the tumor by antibody binding and complement-mediated cytotoxicity. Thus at 
the time of diagnosis, antibodies are present but no tumor is detected. A better understanding of 
the events that trigger the immune response in anti-NMDA receptor encephalitis and other 
autoimmune encephalitides will be important in both treatment and prevention of these and other 
related disorders. 
 
The source and brain access of autoantibodies to synaptic antigens 
Two possible, not mutually exclusive, mechanisms that explain the presence of synaptic 
autoantibodies in the CNS include passive IgG crossing of the BBB and intrathecal or cerebral 
synthesis of antibodies by plasma cells (see Fig 1).  
The first possibility is that antibodies synthesized in the periphery cross a pathologically 
disrupted BBB, or through regions where the BBB is normally leaky (area postrema) or more 
susceptible to systemic changes (e.g. stress, high blood pressure). Several methods for 
experimentally increasing BBB permeability have been described in the literature, including focal 
ultrasound,64 hypertonic solute65,66 and lipopolysaccharide.67 More physiologically relevant 
models of BBB disruption include peripheral inflammation,68,69 acute stress70 and epinephrine.71 
Several studies have shown that peripherally administered antibodies can access the brain 
following these breaches in BBB integrity. Iodinated antibodies injected into rats were detected in 
the brain following osmotic opening of the BBB.66 Kinoshita et al.64 showed that focal sonication 
caused BBB disruption, allowing intravenously injected dopamine receptor antibodies to enter the 
brain and bind to antigen at sites of barrier breakdown. 
The second possibility is that antibodies are synthesized intrathecally. Most patients with 
anti-NMDA, -AMPA or -GABAB receptor encephalitis have an increased ratio of CSF to serum 
IgG concentration, indicating intrathecal synthesis of antibodies. Moreover, protein electrophoretic 
analyses of the CSF of these patients often demonstrate multiple distinct bands of IgG that are 
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absent in serum (oligoclonal bands), suggesting the presence of plasma cell clones within the 
thecal space that secrete distinct immunoglobulins.12 Extensive clinical and immunological data 
from patients with anti- NMDA receptor encephalitis suggest a model in which both passive 
crossing and intrathecal synthesis of antibodies occur. Given that most patients present with 
prodromal symptoms (hyperthermia, undetermined viral-like infection) it is likely that the BBB is 
transiently disrupted. This is supported by studies showing transient FLAIR (fluid attenuation 
inversion recovery) MRI changes involving cortical or subcortical regions. Additionally, after 
systemic immune activation by an NMDA receptor-expressing tumor or other unknown factors, 
memory B cells that are able to cross a normal BBB will undergo re-stimulation, antigen-driven 
affinity maturation, clonal expansion and differentiation into NMDA receptor antibody-secreting 
plasma cells. This mechanism, which has been reported in other autoimmune diseases such as 
multiple sclerosis,72 would explain the detection of intrathecal synthesis of antibodies in most 
patients with anti-NMDA receptor encephalitis. Moreover, the occurrence of both passive BBB 
transfer and intrathecal synthesis of antibodies explains the increasing symptom refractoriness to 
predominant serum IgG depleting strategies (intravenous Ig, plasma exchange) during the course 
of the disease. Patients who do not respond to these treatments often improve with 
cyclophosphamide and rituximab, which are more effective in reducing intrathecal synthesis of 
antibodies. A better understanding of the site and dynamics of antibody synthesis during the 
course of these disorders is crucial for improving treatment methods and delivery. 
 
Mechanisms underlying antibody pathogenic effects on the target receptors 
Several mechanisms may account for the pathogenicity of autoantibodies in autoimmune 
encephalitides. These include agonizing or antagonizing the receptor, causing receptor 
internalization and degradation resulting in diminished receptor function, or stimulating 
complement-mediated neuronal damage. Each of these effects has been demonstrated in 
autoimmune diseases of the nervous system, and in some, more than one of these effects 
contributes to the disease process. 
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The first possibility is that patient anti-receptor antibodies agonize or antagonize the 
receptor. NR2 antibodies from patients with SLE cause neuronal death when injected into mouse 
brain; this effect is attenuated by treatment with the NMDA receptor blocker MK-801, suggesting 
the antibodies mediate cell death by enhancing channel activation.62 Conversely, application of 
nicotinic acetylcholine receptor (nAChR) antibodies from myasthenia gravis patients to outside-
out patches of mouse myotubes caused an acute block of AChR currents that became 
irreversible with time.73 With respect to patient NMDA and AMPA receptor antibodies, there is no 
clear evidence supporting direct agonism or antagonism of receptor function. However, the fact 
that the epitope for both NMDA receptor and AMPA receptor antibodies is in the N-terminus 
raises the possibility that autoantibodies could have direct functional effects. The ligand-binding 
domain for both channels is also in the N-terminus, and conformational changes are thought to 
couple	  ligand binding to channel opening.74,75 Therefore, patient antibodies could sterically hinder 
ligand binding or enhance its effects. In addition, N-terminal binding sites for channel modulators 
such as zinc and polyamines may be obscured by patients’ antibodies.76-78 Whole-cell recording 
experiments during acute application of antibodies will allow this issue to be resolved. 
The second possibility is that patient anti-receptor antibodies cause receptor 
internalization and degradation, resulting in diminished receptor function. AChR antibodies from 
patients with myasthenia gravis cause a loss of surface receptors by cross-linking and 
internalization.79 Cross-linking and internalization of voltage-gated calcium channels by 
autoantibodies has also been shown to occur in patients with Lambert–Eaton syndrome.80,81 In 
anti-NMDA receptor encephalitis, we have shown that the loss of surface NMDA receptors is the 
result of antibody-mediated cross-linking and internalization (see Fig 2). Treatment of cultured 
neurons with monovalent F(ab) fragments generated from patients’ antibodies did not induce 
receptor internalization, but subsequent cross-linking with anti-F(ab) antibodies restored the 
decrease caused by intact patient NMDA receptor antibodies.26 These data demonstrate that 
patients’ antibodies produce both structural and functional changes at the synapse. Determining 
the range of effects of patients’ antibodies (short-term, long-term and dynamics of recovery) will 
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provide insight into the synaptic basis of the memory and behavioral changes seen in these 
patients, and help to establish the roles of NMDA receptor signaling in human behavior and 
cognition. 
The third possibility is that patient anti-receptor antibodies cause complement-mediated 
neuronal damage or death. Muscle biopsies from patients with myasthenia gravis have revealed 
extensive deposits of components of the complement cascade.82,83 Autopsy and in vitro studies 
have also linked complement activation to Rasmussen’s encephalitis and neuromyelitis optica, 
the latter characterized by antibodies to aquaporin-4.84-86 IgG1 and IgG3, subclasses of IgG 
capable of activating complement, are the main IgG types of NMDA and AMPA receptor 
antibodies. In anti-NMDA receptor encephalitis, we have not found evidence of deposits of 
complement in autopsies of patients. In light of the substantial recoveries made by many of these 
patients, extensive neuronal damage due to complement activation seems unlikely. Furthermore, 
it is unclear whether the elements of the complement cascade that are present in the central 
nervous system are sufficient to induce complement-mediated lysis. Further studies are needed 
to determine the degree of involvement of complement-mediated mechanisms in the brain and 
tumors of patients with synaptic autoimmune encephalitis. 
 
Homeostatic compensatory changes in response to antibody-mediated decreases of 
receptor levels 
Compensatory mechanisms at the cellular and synaptic level have been shown to occur 
in autoimmune disorders of the nervous system in humans and in experimental model systems. 
Studies from mouse models of myasthenia gravis and patients’ tissue have shown an enhanced 
rate of synthesis of AChRs and increased expression levels of the α, β, δ and ε subunits of the 
AChR, as well as increased acetylcholine release upon stimulation.47,87-89 Purkinje cells treated 
with IgG from patients with Lambert-Eaton syndrome show a loss of P ⁄ Q-type	  voltage-gated 
calcium channel currents and a concomitant increase in R-type currents.90 Deletion of the α-1a 
subunit of the  P ⁄ Q-type channel in mice causes age-related ataxia and muscle weakness and 
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results in enhanced L- and N-type calcium channel currents in Purkinje cells.91 These 
observations raise the possibility that homeostatic mechanisms occur in anti-NMDA receptor and 
anti-AMPA receptor encephalitis, although this remains to be demonstrated. Support for this idea 
comes from the changes in synaptic strength observed after pharmacological blockade of 
glutamate receptors. Several studies have shown that, after 48 hours of NMDA or AMPA receptor 
blockade, miniature excitatory postsynaptic current (mEPSC) amplitude is enhanced.92,93 
 
Effects of maternal antibodies on fetal development and subsequent behavior 
Although the symptoms of anti-NMDA receptor encephalitis are largely similar between 
children and adults, children tend to have less severe autonomic problems and increased speech 
dysfunction.17,94 These differences, along with a subset of patients who were diagnosed during 
pregnancy, raise questions about the effects of anti-receptor antibodies on the developing brain, 
and the long-term consequences of fetal or pediatric exposure to the antibodies.  
Several other autoimmune diseases are associated with abnormalities in offspring. 
Children born to mothers with SLE, especially male children, have higher rates of developmental 
and learning disabilities than children born to unaffected mothers.95,96 In mice, in utero exposure 
to antibodies from SLE patient serum results in morphological and behavioral abnormalities in 
offspring.97 Maternal myasthenia gravis is often associated with arthrogryposis multiplex 
congenita, a condition caused by lack of fetal movements that is associated with joint 
contractures and muscle weakness in offspring.98 Interestingly, asymptomatic women who have 
children with this condition may harbor anti-AChR antibodies. Serum from these women contains 
antibodies only to a fetal subunit of the AChR, and is therefore specifically harmful to the fetus 
rather than the mother.99,100 These studies highlight the devastating effects that maternal 
autoantibodies can have on fetal development.	  	  
Studies of mothers of autistic children also raise the possibility that maternal antibodies 
may impact fetal development. Several studies of these women have suggested that they harbor 
anti-neuronal antibodies in their serum, although the antigen(s) is unknown. For example, serum 
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from a woman with an autistic child and a child with a severe language disorder contained 
antibodies that bound rodent neurons and caused behavioral and motor abnormalities in mice 
exposed to the serum as embryos.101 In addition, serum from mothers with autistic children 
caused hyperactivity and stereotypic behavior in rhesus monkeys exposed prenatally to the 
serum.102 These results show that asymptomatic women may have circulating neuronal 
antibodies that have access to the fetal brain and may affect brain development. 
Two women who developed anti-NMDA receptor encephalitis at 14 and 17 weeks of 
pregnancy, when the specific transplacental transfer of IgG1 and IgG3 is not yet fully developed, 
delivered apparently normal newborns. Studies performed in one of the babies showed a lack of 
antibodies in serum and CSF.103 However, given the importance of synaptic activity, in particular 
glutamatergic and GABAergic transmission during neural circuit development,	  in utero exposure 
to antibodies from patients with anti-NMDA receptor encephalitis, or other autoimmune 
encephalitides, may potentially affect normal fetal brain development, resulting in neurological 
and behavioral disturbances in offspring. Thus, establishing a mechanistic link between anti-
receptor antibodies, access to the developing brain, effects on synapses and circuits and 
ultimately behavior, assayed across a life span, will be important for resolving these issues in a 
broad spectrum of disorders. 
 
Relating the effects of synaptic receptor antibodies to neurological symptoms 
Glutamate binding to NMDA receptors and AMPA receptors is crucial for synaptic 
transmission and plasticity. Pharmacological blockade or genetic reduction of these receptors has 
been shown to alter learning and memory and other behaviors in animal models.104-111 The 
balance between excitatory and inhibitory synaptic inputs is also altered, and this has been 
shown to affect circuit function and behavior.112-118 In addition, NMDA119-126 and ⁄ or AMPA127-131 
receptor hypofunction has been proposed to be part of the pathophysiological mechanisms 
underlying schizophrenia. 
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It is interesting to consider why patients with anti-NMDA receptor antibodies develop a 
complex syndrome that includes psychosis, learning and memory dysfunction, abnormal 
movements, autonomic instability and frequent hypoventilation, whereas those with AMPA 
receptor antibodies preferentially develop psychiatric and amnestic symptoms. Studies using 
genetic deletions of NMDA or AMPA receptor subunits in mouse models provide some insight 
into this issue. Whereas NR1 knockout mice die shortly after birth due to hypoventilation,132 mice 
with spatially restricted NR1 deletion can survive into adulthood.133 CA1- specific NR1 knockouts 
have impaired spatial and temporal memory and a loss of CA1 long-term potentiation (LTP).134 
Mice with an inducible, reversible knockout of NR1 in forebrain show impairment in the 
maintenance of long-term memory if NR1 expression is turned off during the memory storage 
phase.135 In addition to memory deficits, targeted manipulation of NR1 expression can result in 
schizophrenia-like symptoms. Hypomorphic expression of NR1 leads to increased stereotypic 
behavior and decreased sociability, while early postnatal loss of NR1 in a subset of cortical and 
hippocampal interneurons results in decreased pre-pulse inhibition and increased social isolation-
induced anxiety.108,136 Moreover, subanesthetic doses of NMDA receptor blockers such as 
phencyclidine and ketamine are psychotomimetic, and they recapitulate many of the positive and 
negative signs of schizophrenia in humans and rodents as well as repetitive orofacial movements, 
autonomic instability and seizures.137-139 The remarkable similarity between these phenotypes, 
the effect of patients’ antibodies resulting in a dramatic decrease of synaptic NMDA receptor 
clusters and function, and the reduced levels of NMDA receptors in autopsied patients support an 
antibody-mediated pathogenesis of anti-NMDA receptor encephalitis, and strengthen the NMDA 
receptor hypofunction hypothesis of schizophrenia.136  
The consequences of loss of AMPA receptor expression have also been studied in 
mouse models. Spatial learning and memory are largely unaffected in GluR1 knockout mice 
despite the fact that LTP is reduced in CA1 and CA3140 and working memory is diminished.141,142 
GluR2 knockout mice show reduced exploration and impaired motor coordination. In these 
animals, AMPA receptor-mediated synaptic transmission is reduced, but LTP is enhanced.143,144 
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GluR2 knockout mice also have increased cell death,145,146 possibly due to excitotoxicity related 
to increased, compensatory insertion of GluR1 homomeric AMPA receptors. Although AMPA 
receptor subunit knockout mice have not provided a satisfying explanation for the role of AMPA 
receptors in synaptic plasticity related to learning and memory, the fact that patients with AMPA 
receptor antibodies have short-term learning and memory deficits argues that further studies at 
the circuit and behavioral levels are warranted. 
 GABAB1 receptor knockout mice display a variety of neurological and behavioral 
abnormalities, including spontaneous seizures, enhanced anxiety, hyperactivity, hyperalgesia and 
impaired memory,37,38 suggesting dysfunction of the limbic system. Consistent with these 
experimental data, patients with anti-GABAB1 receptor antibodies present with an encephalitis 
that associates with early and prominent seizures, confusion, agitation, behavioral problems and 
severe short-term memory deficits along with MRI abnormalities predominantly involving the 
hippocampi. Interestingly, both GABAB1 receptor knockout mice and mice treated with a GABAB1 
receptor antagonist, CGP56433A, exhibit antidepressant-like behavior in a forced swim test and a 
learned helplessness paradigm,147,148 suggesting that GABA signaling may have disparate effects 
on different aspects of mood such as depression and anxiety. Combined with animal studies, 
these patients can provide rich insight into the role of GABAB1 receptor signaling in memory, 
behavior and cognition. 
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Conclusions 
We have begun to obtain a better cellular- and synaptic-level understanding of a new and 
remarkable group of immune-mediated behavioral and memory disorders. On the clinical side, we 
would like to know the frequency of these antibodies in patients with milder or form frustes of the 
syndromes (e.g. predominant psychosis, isolated refractory seizures), and whether the effects of 
antibodies on glutamate and GABA receptors, and synapses, vary according to different 
subgroups of patients, improving the diagnostic and treatment strategies. It is likely that the 
effects of antibodies on children (or antibody effects on immature hippocampal synapses) are 
different from those on adults (or on mature hippocampal synapses), and this may account for 
some of the behavioral differences between adults and children. Another critical issue is the 
optimal type of immunotherapy at different stages of the disease, and the duration of treatment. In 
current clinical practice, most patients receive intravenous immunoglobulins, plasma exchange 
and corticosteroids as the first line of therapy. When these fail, rituximab (a B-cell-depleting 
monoclonal antibody) and cyclophosphamide are increasingly being used in an attempt to modify 
the levels of antibodies behind the BBB. However, it is unclear whether or how these treatments 
modify the effects of antibodies on synapses. 
On the basic neuroscience side, a major goal will be to develop and test rodent models in 
a battery of behavioral tests designed to assay hippocampal, amygdala, cortical and cerebellar 
function in each disorder. In this way, we can begin to relate the cellular, synaptic and circuit 
effects of patients’ antibodies to behavioral deficits in learning, memory, and other cognitive and 
motor manifestations. 
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Figure 1. Mechanisms involved in the presence of antibodies in the central nervous 
system.  
(A, B) In a subset of anti-NMDA receptor encephalitis patients, an immune response is initiated 
against neuronal antigens expressed by an ovarian teratoma or another tumor (A). In another 
subset of patients, the immunological trigger is unknown (B). The ectopic expression of NMDA 
receptors by a tumor or other mechanisms (e.g. molecular mimicry) breaks down immune 
tolerance by a sequence of events including antigen presentation by T or dendritic cells 
generating memory B cells (1) and antibody-producing plasma cells (2). Systemically synthesized 
antibodies can bind to NMDA receptors present in the tumor and behind a disrupted or leaky 
blood–brain barrier (BBB) (4). Disruption of the BBB is likely to occur early in the disease 
process. In addition, memory B cells (probably also activated T cells) that are able to cross a 
normal BBB (5) will undergo re-stimulation (resident antigen presenting cells or T cells, 6), 
antigen-driven affinity maturation, clonal expansion and differentiation into NMDA receptor 
antibody-secreting plasma cells (7). Antibodies produced within the CNS by plasma cells (8) or 
reaching the CNS by BBB disruption (4) bind to extracellular epitopes of NMDA receptor (9) 
causing subsequent internalization (see Fig 2). 
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Figure 2. Mechanisms underlying cellular and synaptic effects of anti-NMDA receptor 
antibodies.  
(A) AMPA and NMDA receptors are localized in the postsynaptic membrane and are clustered at 
the postsynaptic density. (B) Patient antibodies in the central nervous system bind selectively to 
NMDA receptors at the synapse as well as extrasynaptic receptors. This binding leads to receptor 
cross-linking. (C) NMDA receptors that have been bound and cross-linked by antibodies are 
internalized, resulting in a decrease of surface NMDA receptors. Other synaptic components, 
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such as postsynaptic AMPA receptor clusters, PSD-95, as well as presynaptic terminals, dendrite 
branches, dendritic spines and cell viability, are unaffected. Thus patient anti-NMDA receptor 
antibodies lead to a rapid, selective loss of NMDA receptors from neuronal membranes. This 
effect is titer-dependent and reverses after antibody titers are reduced (not shown). (D, E) Rodent 
cultured neurons treated with control or patient CSF for 3 days, and subsequently stained for NR1 
to label NMDA receptor clusters, vGlut to label presynaptic sites and PSD-95 as a postsynaptic 
marker. Note that patient CSF causes a decrease in dendritic NR1 cluster density, while vGlut 
and PSD-95 cluster density remains unchanged. (F, G) Whole-cell patch-clamp recordings of 
miniature excitatory postsynaptic currents (mEPSCs), which consist of a fast AMPA receptor-
mediated component and a later, slower NMDA receptor-mediated component that is APV 
sensitive. Compared with neurons incubated with control CSF (F), those treated with CSF from a 
patient with NMDA receptor antibodies show a selective loss of the APV-sensitive NMDA receptor 
component (G).
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Table 1: Immune-mediated disorders of the synapse 
Antigen Syndrome/ 
symptoms 
Patient 
antibody 
effects on 
receptors 
Criteria Clinical 
references 
Molecular 
references 
Central nervous system disorders 
NR1 subunit 
of NMDA 
receptor 
Anti-NMDA 
receptor 
encephalitis ⁄ 
psychosis, 
behavioral and 
memory deficits, 
dyskinesias, 
language 
reduction (in 
children), 
seizures, 
autonomic 
instability 
Decreased 
synaptic 
NMDARs; 
decreased 
NMDAR-
mediated 
mEPSCs 
1-4, 6 Dalmau et 
al., 2007 
Dalmau et al., 
2008; 
Hughes et al., 
2010 
GluR1/2 
subunit of 
AMPA 
receptor 
Anti-AMPA 
receptor 
encephalitis ⁄ 
short-term 
memory deficits, 
seizures, 
psychiatric 
manifestations; 
tendency to 
relapse 
Decreased 
synaptic 
AMPARs; 
decreased 
AMPAR-
mediated 
mEPSCs 
1-3, 6 Lai et al., 
2009 
Lai et al., 
2009 
GABAB1 
receptor 
Anti-GABAB1 
receptor 
encephalitis ⁄ 
seizures, short-
term memory 
deficits 
Pending 
character- 
ization 
1-2, 4 Lancaster 
et al., 2009 
 
NR2A/ 
NR2B 
subunits of 
NMDA 
receptor 
Neuropsychiatric 
systemic lupus 
erythematosus ⁄ 
cognitive deficits, 
psychosis, 
memory deficits, 
mood disorder, 
seizure, headache 
NMDAR 
agonism 
1, 3, 5 Brey et al., 
2002 
DeGiorgio et 
al., 2001; 
Kowal et al., 
2006 
Voltage-
gated K+ 
channel 
Neuromyotonia, 
limbic 
encephalitis, 
Morvan’s 
syndrome ⁄ muscle 
spasticity, 
memory deficit, 
insomnia, 
hallucinations 
 1, 2, 4, 
(5 only 
features of 
neuromyo
-tonia), 6 
Vincent et 
al., 2004 
Kleopa et al., 
2006; 
Shillito et al., 
1995; 
Rho et al., 
1999 
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Peripheral nervous system disorders 
Nicotinic 
acetylcholine 
receptors 
Myasthenia gravis/ 
muscle weakness, 
fatigue 
Decreased 
synaptic 
AChRs at 
neuromuscular 
junctions; 
decreased 
AChR-
mediated 
currents 
1-6 Dau et al., 
1977; 
Meriggioli 
and 
Sanders, 
2009 
Toyka et al., 
1975; 
Lennon et al., 
1985; 
Missias et al., 
1997; 
Jahn et al., 
2000; Leite 
et al., 2008; 
Lang & 
Vincent, 2009 
Voltage-
gated Ca2+ 
channel 
Lambert–Eaton 
syndrome ⁄ muscle 
weakness 
Decreased 
presynaptic 
channels at 
neuromuscular 
junctions; 
decreased 
neuro-
transmitter 
release 
1-6 Leys et al., 
1989; 
Motomura 
et al., 
2000; 
Pourmand, 
2009 
Fukunaga et 
al., 1983; 
Lang et al., 
1983; 
Takamori et 
al., 2000; 
Kim, 1985; 
Molenaar, 
2008; Nagel 
et al., 1988; 
Peers et al., 
1993; Pinto et 
al., 2002 
Ganglionic 
nicotinic 
acetylcholine 
receptor 
Peripheral 
neuropathy, 
autonomic 
nervous system 
dysfunction 
Reduction in 
AChR current 
due to antibody 
cross-linking 
1-6 Vernino et 
al., 1998, 
2000 
Xu et al., 
1999; 
Vernino et al., 
2004, 2008; 
Wang et al., 
2007 
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Abstract 
 Objective: A severe but treatable form of immune-mediated encephalitis is associated 
with antibodies in serum and cerebrospinal fluid (CSF) against the GluN1 subunit of the N-methyl-
D-aspartate receptor (NMDAR). Prolonged exposure of hippocampal neurons to antibodies from 
patients with anti-NMDAR encephalitis caused a reversible decrease in the synaptic localization 
and function of NMDARs. However, acute effects of the antibodies, fate of the internalized 
receptors, type of neurons affected, and whether neurons develop compensatory homeostatic 
mechanisms were unknown and are the focus of this study. 
Methods: Dissociated hippocampal neuron cultures and rodent brain sections were used 
for immunocytochemical, physiological, and molecular studies. 
Results: Patient antibodies bind to NMDARs throughout the rodent brain, and decrease 
NMDAR cluster density in both excitatory and inhibitory hippocampal neurons. They rapidly 
increase the internalization rate of surface NMDAR clusters, independent of receptor activity. This 
internalization likely accounts for the observed decrease in NMDAR-mediated currents, as no 
evidence of direct blockade was detected. Once internalized, antibody-bound NMDARs traffic 
through both recycling endosomes and lysosomes, similar to pharmacologically-induced NMDAR 
endocytosis. The antibodies are responsible for receptor internalization, as their depletion from 
CSF abrogates these effects in hippocampal neurons. We find that although anti-NMDAR 
antibodies do not induce compensatory changes in glutamate receptor gene expression, they 
cause a decrease in inhibitory synapse density onto excitatory hippocampal neurons. 
Interpretation: Our data support an antibody-mediated mechanism of disease 
pathogenesis driven by immunoglobulin-induced receptor internalization. Antibody-mediated 
down-regulation of surface NMDARs engages homeostatic synaptic plasticity mechanisms, which 
may inadvertently contribute to disease progression. 
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Introduction 
 Glutamatergic transmission is central to many functions thought to depend on synaptic 
plasticity, including learning and memory, cognition, and behavior.1,2 Several newly described 
immune-mediated encephalitides that target synaptic antigens have offered novel insights into the 
link between synapse function and human cognition and behavior.3,4 One form of autoimmune 
encephalitis is associated with antibodies against the N-methyl-D-aspartate receptor (NMDAR).5,6 
Consistent with the prominent role of NMDARs in glutamatergic transmission as well as activity 
dependent plasticity, symptoms of anti-NMDAR encephalitis include sudden behavioral, memory, 
and personality changes that progress to seizures, autonomic instability, and coma. If left 
untreated, irreversible deficits and death can occur. Immunotherapy treatment leads to a 
substantial to full recovery for about 80% of patients.7  
NMDARs, along with a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and 
kainate receptors, mediate glutamatergic synaptic transmission and have a prominent role in 
synaptic plasticity, learning, and behavior. Pharmacological blockade or genetic reduction of 
NMDARs alters learning and memory,8–10 excitatory–inhibitory balance,11,12 and behavior.13–15 
Defects in glutamate signaling have been linked to neuropsychiatric disorders, and NMDAR 
hypofunction has been proposed to be part of the pathophysiological mechanisms underlying 
schizophrenia.16 Subanesthetic doses of NMDAR blockers such as phencyclidine and ketamine 
are psychotomimetic in humans and rodents, and cause the stereotypic movements, autonomic 
instability, and seizures that are characteristic of anti-NMDAR encephalitis.17,18 
The striking parallels between patient symptoms and the consequences of NMDAR 
hypofunction described above underscore the importance of determining the mechanisms of 
antibody-mediated dysfunction in this disease. Patient antibodies cause a selective, reversible 
decrease of NMDAR surface density, synaptic localization, and currents in vitro.6,19,20  Here, we 
explored mechanisms of disease pathogenesis, investigating whether patient antibodies 
preferentially bind to NMDARs on specific types of neurons or brain regions, the time course of 
receptor internalization, whether antibodies directly antagonize the receptor, whether components 
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besides immunoglobulins within patient cerebrospinal fluid (CSF) can contribute to down-
regulation of NMDARs, and whether neurons engage homeostatic mechanisms in response to 
the decrease in glutamatergic transmission. Understanding the acute mechanisms of antibody-
mediated dysfunction sets the stage for future studies in in vivo models of anti-NMDAR 
encephalitis. 
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Materials and Methods 
Cell culture and treatment 
Hippocampal neurons were prepared and maintained from embryonic day 18 rat pups as 
previously described.19 Neurons were treated on in vitro day 14 (DIV14; unless otherwise noted) 
with CSF from patients or controls at a dilution of 1:20, and drugs at the following concentrations: 
amino-phosphonovaleric acid (APV), 50µM; picrotoxin, 10µM; NMDA, 1mM; glycine, 10µM. 
Cerebrospinal fluid and serum were obtained from randomly selected patients with well-
characterized clinical manifestations of anti-NMDAR encephalitis. Antibodies to the NMDAR were 
demonstrated as previously reported.6 Control samples were obtained from patients undergoing 
CSF screening for various disorders not associated with antibodies against the NMDAR. 
 
Immunostaining 
Immunostaining protocols for cultured neurons and rodent brain sections have been described in 
detail elsewhere.19 Neurons were treated as specified in the text and incubated with the following 
primary antibodies: to label NMDARs, anti-GluN1 (Millipore, Billerica, MA; AB9864R, 1:100) and 
anti-GluN1 (Sigma, St Louis, MO; G8913, 1:100); inhibitory neurons, anti–glutamic acid 
decarboxylase 6 (GAD6; Developmental Studies Hybridoma Bank, Iowa City, IA; 1:20; the 
monoclonal antibody was developed by Dr David I. Gottlieb at Washington University School of 
Medicine and is maintained at the University of Iowa); presynaptic terminals, anti-bassoon 
(Stressgen Bioreagents, Ann Arbor, MI; VAM-PS003, 1:400); recycling endosomes, anti-Rab11 
(Zymed Laboratories, San Francisco, CA; 71–5300, 1:100); lysosomes, anti-Lamp1 (Enzo Life 
Sciences, Plymouth Meeting, PA; ADI-VAM-EN001, 1:100); amino-butyric acid receptors 
(GABAARs), anti-GABAAβ2/3 (Millipore, 05–474, 1:500); and presynaptic inhibitory terminals, anti-
vesicular GABA transporter (vGAT; Synaptic Systems, Gottingen, Germany; 131-004, 1:1,000). 
Manufacturer’s websites provide controls for specificity of all primary antibodies used. Omission 
of primary antibodies was used as a control for each of the secondary antibodies, which were 
raised in goat against rabbit, mouse, or guinea pig immunoglobulin G (IgG) and conjugated to 
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various Alexa Fluor dyes. All secondary antibodies were obtained from Invitrogen (Carlsbad, CA). 
Coverslips were mounted and imaged on a confocal microscope (Leica, Wetzlar, Germany; TCS 
SP5) and analyzed using interactive software (custom-written ImageJ macros).19 To selectively 
label internalized NMDARs, surface NMDARs were bound by incubation with patient CSF (1:20). 
After treatment, coverslips were incubated with unconjugated goat anti-human secondary 
antibody at 1:10. Then, neurons were fixed, permeabilized, and stained with fluorescently 
conjugated goat anti-human secondary antibody, which only labeled internalized receptors due to 
the saturation of surface receptors by unlabeled antibody. To label surface and internal receptors, 
after incubation with patient antibodies, the remaining surface antibody-bound receptors were 
labeled with a fluorescent secondary antibody. Neurons were fixed, permeabilized, and stained 
with a different secondary antibody against human IgG to label the internalized antibody-bound 
receptors, as well as anti-GluN1 to label the total population of NMDARs. To induce NMDAR 
internalization pharmacologically, we used 2 different treatment protocols. The first was a 24-hour 
incubation with picrotoxin, which blocks inhibitory GABAAR-mediated synaptic transmission, 
causing a homeostatic decrease of NMDARs.21 The second was a 15-minute exposure to NMDA 
plus glycine, which activates the NMDAR and causes rapid internalization.22 
 
Electrophysiology 
Electrophysiology protocols have been described in detail elsewhere.19 Whole cell voltage clamp 
recordings were made from DIV17–21 neurons that had been treated for 30 minutes with patient 
or control CSF, or 24 hours with patient F(ab) fragments. Extracellular physiological solution was 
(in millimolars): 119 NaCl, 5 KCl, 2 CaCl2, 30 glucose, 10 HEPES, pH=7.4. For excitatory 
currents, intracellular pipet solution was (in millimolars): 100 cesium gluconate, 0.2 
ethyleneglycoltetraacetic acid (EGTA), 5 MgCl2, 2 adenosine triphosphate, 0.3 guanosine 
triphosphate, 40 HEPES, pH=7.3. For inhibitory currents, intracellular solution was (in 
millimolars): 140 KCl, 2 MgCl2, 11 EGTA, 10 HEPES, 7 glucose, pH=7.3. Tetrodotoxin (TTX) 
(1µM) was used to block action potentials, picrotoxin (10µM) was used to block GABAAR-
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mediated miniature inhibitory postsynaptic currents (mIPSCs), cyanonitroquinoxaline-dione 
(CNQX) (10µM) was used to block AMPAR-mediated miniature excitatory postsynaptic currents 
(mEPSCs), and APV (50µM) was used to block NMDAR-mediated mEPSCs. Spontaneous 
miniature postsynaptic currents were detected and analyzed using MiniAnalysis (Synaptosoft, 
Leonia, NY). NMDAR and AMPAR components of mEPSCs were separated temporally by their 
distinct kinetics. The amplitude of the NMDAR-mediated current was determined in a window 
between 15 and 25 milliseconds after the peak of the averaged AMPAR-mediated component, 
which has a fast, <1-millisecond rise time.19 
 
F(ab) fragment preparation 
F(ab) fragments were prepared from patients’ serum whole IgG using a kit according to the 
manufacturer’s directions (Pierce Fab Micro Preparation Kit; Thermo Scientific, Waltham, MA).	  	  
	  
Immunodepletion 
Patient CSF was incubated on 50:50 Protein A and rProtein G agarose column (Invitrogen) 
equilibrated in binding buffer (0.01M sodium phosphate, pH=7.0, 0.15M sodium chloride). The 
column was rocked for 1 hour at room temperature, and CSF was collected and stored at -20°C 
until use. 
 
Statistical analysis 
Data sets were analyzed using a Mann-Whitney U test or one-way analysis of variance test. 
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Results 
Patient and commercial GluN1 antibodies were similarly distributed after immunostaining 
Patient antibodies stained rat hippocampus in sections more intensely than other brain 
regions, such as cortex, striatum, and hindbrain.6 To determine whether this pattern was due to a 
modification of the epitope specific to the hippocampus, or due to a higher expression of 
NMDARs within the hippocampus, we asked whether the staining pattern of patient antibodies 
was the same as that of 2 commercially available antibodies that recognize epitopes within the 
intracellular, C-terminal domain of GluN1. 
Staining with commercial antibodies produced the same enrichment in hippocampal 
immunoreactivity as patient CSF (Fig 1A). Patient and commercial antibodies both stained cortex, 
striatum, and cerebellum as well as hippocampus, although less intensely. The difference in 
overall staining intensity between the sample on the left (Patient 1) and on the right (Patient 2) is 
due to a difference in the patients’ antibody titers. Double labeling with patient and commercial 
antibodies showed their considerable colocalization in the dendritic layers of the dentate gyrus 
(see Fig 1B). These results suggest that the observed preferential hippocampal staining of patient 
antibodies is due to a higher density of NMDARs within the hippocampus compared with other 
regions. 
 
Patient antibodies decreased surface NMDARs on excitatory and inhibitory hippocampal neurons 
We asked whether the effects of patient antibody treatment differed between excitatory 
and inhibitory neurons, potentially disrupting the excitatory–inhibitory balance, as occurs following 
administration of some NMDAR antagonists that cause symptoms similar to anti-NMDAR 
encephalitis.11,23 Cultured hippocampal neurons were treated with control or patient CSF, then 
stained for surface NMDARs, total GluN1, and GAD6 to label inhibitory neurons. Inhibitory 
neurons were identified by strong immunoreactivity of GAD6 in cell bodies. 
In excitatory, GAD-negative neurons, patient CSF treatment caused a significant 
decrease in surface NMDAR cluster density compared with control CSF (Fig 2). A similar result 
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was seen in inhibitory, GAD-positive neurons. Patient antibodies also caused a decrease in the 
intensity of surface NMDAR clusters. There was no difference in the density of surface NMDAR 
clusters recognized by patient antibodies in these two populations of neurons in control 
conditions. Thus, there is a lack of regional or neuronal subtype specificity in the binding and 
effects of patient antibodies, suggesting broad actions of anti-NMDAR antibodies on cell types 
across brain regions. 
 
Patient antibodies increased the rate of NMDAR internalization in a time-dependent and 
activity-independent manner 
We next wanted to study the time course and dynamics of NMDAR internalization. 
Hippocampal neurons were treated with patient antibodies or patient F(ab) fragments (previously 
shown not to decrease surface NMDAR clusters19) for 15 minutes to 48 hours. Surface NMDAR 
cluster density was significantly decreased compared with F(ab) treatment after 12 hours of 
exposure to patient antibodies (Fig 3A, B). There was no further reduction with longer treatment. 
The accumulation of internalized NMDAR clusters followed the same time course, also reaching a 
maximum by 12 hours of treatment. 
We next examined whether internalization was stimulated by any mechanism other than 
antibody-mediated cross-linking. For example, activation of glutamate receptors can prime them 
for internalization.22 Agonism by patient antibodies could decrease surface NMDAR levels by 
similar mechanisms. This could change our understanding of the effects of patient antibodies on 
NMDARs, and point to new options for patient care. To test this possibility, hippocampal neurons 
were treated with control or patient CSF with or without APV, an NMDAR blocker, then stained for 
surface NMDARs, bassoon (for presynaptic terminals), and total GluN1. 
As expected, patient CSF caused a significant decrease in synaptic NMDAR clusters 
(see Fig 3C, D). This effect was not mitigated by the presence of APV, demonstrating that 
antibody-mediated internalization was independent of NMDAR activity and did not occur as a 
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compensatory response to agonism of the receptor. Therefore, the mechanism of internalization 
is likely due primarily to the effects of NMDAR cross-linking by patient antibodies. 
 
Patient antibody-bound receptors trafficked through recycling endosomes and lysosomes 
In anti-NMDAR encephalitis, NMDARs are bound by immunoglobulins during 
endocytosis, a scenario that would not occur under physiological conditions of receptor 
internalization. To examine whether intracellular NMDAR trafficking was influenced by this unique 
situation, we compared patient antibody treatment with 2 pharmacological manipulations that 
caused NMDAR internalization, picrotoxin (a GABAAR blocker) and NMDA/glycine. 
Hippocampal neurons were treated with one of the following: patient CSF for 24 hours, 
patient F(ab) fragments for 24 hours, F(ab) fragments plus picrotoxin for 24 hours, or F(ab) 
fragments for 24 hours plus NMDA/glycine for 15 minutes (see Materials and Methods). F(ab) 
fragments allowed us to track NMDAR internalization induced by pharmacological treatment, 
without the complication of full patient immunoglobulin (IgG) further stimulating endocytosis (see 
Fig 3A, B). Following treatment, neurons were stained for internalized NMDARs, and Rab11 and 
Lamp1, markers for recycling endosomes and lysosomes, respectively. 
Patient CSF, picrotoxin, and NMDA/glycine all caused a significant increase in NMDAR 
internalization compared with F(ab) fragments alone (Fig 4). Between the 3 conditions that 
promoted internalization, there was no significant change in the proportion of internalized 
NMDARs that localized to recycling endosomes or lysosomes. Additionally, for all 3 conditions, a 
greater percentage of internalized receptors colocalized with recycling endosomes than 
lysosomes. These data suggest that the post-endocytic trafficking of NMDARs is not affected by 
IgG binding the receptor.  
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Patient CSF caused NMDAR hypofunction through immunoglobulin-induced receptor 
internalization 
Patient antibodies could potentially modulate receptor function independently of their 
ability to internalize NMDARs because the epitope is within the N-terminus of GluN1,24 a region 
that also contains the ligand binding domain. To test this possibility, we first performed whole-cell 
patch-clamp recordings of mEPSCs from hippocampal neurons on DIV17–21 that had been 
treated with control or patient CSF for 30 minutes, a time point before significant internalization of 
NMDARs has occurred (see Fig 3A, B). NMDAR-mediated current amplitudes from neurons 
treated for only 30 minutes with patient CSF were not significantly different from current 
amplitudes in neurons treated with control CSF (Fig 5). Consistent with this finding, we also 
observed that exposure for 24 hours to F(ab) fragments, which were incapable of triggering 
receptor internalization (see Fig 3A, B), did not result in a significant decrease in NMDAR-
mediated current amplitude. Both of these findings were in contrast to the large reduction in 
NMDAR-mediated mEPSC amplitude that resulted from 24 hours of treatment with patient CSF,19 
and provide physiological evidence to support the notion that antibody-mediated NMDAR 
hypofunction results from receptor internationalization and not an acute antagonism of receptor 
function. 
We next asked whether other factors within patient CSF, such as cytokines or 
complement components, were necessary for NMDAR internalization. We previously 
demonstrated that IgGs from patient serum and CSF were sufficient to decrease NMDAR cluster 
density,19 but whether they were also necessary to do so remained unknown. Hippocampal 
neurons were stained with IgG-depleted patient CSF to confirm complete depletion, then treated 
with control CSF, patient CSF, or IgG-depleted CSF, and stained for surface and total NMDARs 
and bassoon. 
Depleted CSF did not retain immunoreactivity on hippocampal neurons, indicating that 
IgGs were successfully depleted from the samples (Fig 6). Unlike patient CSF, treatment with 
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depleted CSF did not reduce NMDAR cluster density, demonstrating that in the absence of IgG, 
patient CSF no longer caused NMDAR internalization. 
These data show that the removal of patient antibodies from CSF abrogates both 
neuronal staining and the effects of patient CSF on surface NMDAR density. Together with 
previous experiments using purified IgG from patient CSF,19 these results demonstrate that 
immunoglobulins within patient CSF are both necessary and sufficient to cause the loss of 
surface NMDARs. 
 
Patient antibodies caused homeostatic plasticity of inhibitory synapse density but not gene 
expression 
We next assessed whether homeostatic plasticity mechanisms were engaged after 
patient antibody-induced NMDAR internalization. We verified that we were able to detect 
homeostatic plasticity in our hippocampal cultures using a pharmacological blocker of NMDARs, 
APV, which had previously been shown to elicit an increase in surface NMDAR levels.25 
Hippocampal neurons were treated for 24 hours with APV, then stained for surface and total 
NMDARs and bassoon. 
In contrast to patient CSF, which caused a significant decrease in synaptic NMDAR 
cluster density (Fig 7A, C), APV treatment resulted in a significant increase. This confirmed that 
homeostatic plasticity was detectable in our experimental system.  
Similar to APV treatment, neurons may attempt to increase NMDAR insertion in response 
to patient antibodies. This would be undetectable due to antibody-mediated internalization of any 
newly inserted receptors. Alternatively, neurons may up-regulate NMDAR transcription after 
internalization. Many genes are transcriptionally regulated by activity,26 and some forms of 
homeostatic plasticity are transcription-dependent.27 To evaluate this possibility, quantitative 
polymerase chain reaction was performed to determine the levels of NMDAR subunit mRNA 
following patient antibody or APV treatment for 24 hours, but no changes were detected in GluN1, 
GluN2A, or GluN2B, or in any of the GluN1 C-terminal splice variants (data not shown). We also 
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measured transcriptional changes in these splice variants after 7 days of treatment, but mRNA 
levels were still unchanged (data not shown). 
We next assayed whether inhibitory synapses displayed homeostatic plasticity in 
response to the NMDAR hypofunction caused by patient antibodies. Evidence suggests a link 
between NMDAR dysregulation and impairments in inhibition,28,29 for example, the frequent 
occurrence of seizures in encephalitis patients that is indicative of defects in inhibitory tone. 
Hippocampal neurons were treated on DIV17–20 with control or patient CSF for 24 hours, then 
whole cell patch clamp recordings of mIPSCs were made. Neither the amplitude nor the 
interevent interval of mIPSCs was changed by patient CSF treatment (see Fig 7C, D; p>0.05). 
Gene expression of GAD1 and GAD2, enzymes responsible for GABA production in inhibitory 
neurons, was also unchanged (data not shown). 
Finally, we treated hippocampal neurons on DIV14 with control or patient CSF for 24 
hours, then fixed and stained for the inhibitory GABAAR and inhibitory presynaptic marker vGAT. 
We found that patient antibody treatment caused a significant decrease in inhibitory synapse 
density (see Fig 7B, D) onto excitatory neurons, which were identified by a lack of vGAT staining 
within the cell body. Together, our data show that although loss of NMDARs does not stimulate 
transcriptional changes of NMDAR subunits or splice variants, neurons are able to partly adjust 
their inhibitory tone in a compensatory direction. 
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Discussion 
This study revealed several novel findings related to the effects of antibodies from 
patients with anti-NMDAR encephalitis, including the lack of neuron subtype specificity, time 
course of the effects, fate of internalized receptors, and homeostatic responses to NMDAR loss. 
In addition, the results confirmed that the major mechanism of dysfunction was loss of NMDARs 
due to IgG-mediated internalization, which likely occurs throughout the brain. The process of 
internalization plateaued after 12 hours, reaching a steady state that persisted throughout 
the duration of treatment. This may reflect the presence of a population of NMDARs unaffected 
by antibodies, or represent a state of equilibrium between the rate of internalization and the rate 
of receptor insertion into the plasma membrane. 
 Internalization of NMDARs can be promoted by receptor activity.22,30 We were unable to 
block patient antibody-mediated NMDAR internalization with APV, suggesting that patient 
antibodies did not exert activity-dependent effects. Electrophysiological analyses also excluded 
direct blockade as a prominent mechanism of antibody-mediated NMDAR hypofunction. These 
results, along with the finding that patient F(ab) fragments did not cause internalization and that 
patient IgG was necessary and sufficient for internalization, suggested that antibody-mediated 
NMDAR internalization was solely due to cross-linking of the receptors. A similar mechanism had 
been demonstrated for myasthenia gravis and Lambert–Eaton syndrome.31 Moreover, human 
autopsy studies of anti-NMDAR encephalitis patients showed deposits of IgG and decreased 
NMDARs, without evidence of cytotoxic T-cell mechanisms, all supporting an antibody-mediated 
pathogenesis.5,32  
NMDARs dynamically traffic into and out of the synapse during physiological processes, 
such as synapse maturation and synaptic plasticity.1 This cycling is largely governed by 
regulatory signals within the C-terminal portions of the receptor complexes that mediate clathrin-
dependent endocytosis.33–35 We showed that internalized, antibody-bound receptors entered a 
recycling and a degradation pathway, although the proportion of internalized receptors in 
recycling compartments consistently exceeded that within lysosomes. Even with different 
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manipulations to induce NMDAR internalization, the trajectory of post-endocytic trafficking was 
unchanged, excluding an immunoglobulin-specific effect. 
Homeostatic plasticity is important for maintaining the stability of neuronal network 
activity in the face of potentially destabilizing changes in the strengths of individual synapses.36 
The NMDAR hypofunction in anti-NMDAR encephalitis led us to the question of whether patient 
antibody treatment can induce homeostatic changes in cultured neurons. We did not detect gene 
expression changes in any NMDAR subunits with either APV or patient antibody treatment, 
concluding that transcriptional regulation was not a major locus of homeostatic plasticity in this 
system. 
We noted the similarity in some symptoms between anti-NMDAR encephalitis and 
schizophrenia. Several lines of evidence in animal models and humans had led to the hypothesis 
that NMDAR hypofunction in inhibitory interneurons led to disinhibition in corticolimbic regions, 
underpinning core symptom domains in schizophrenia.16,37 We examined whether patient 
antibodies may have had disparate effects on excitatory and inhibitory neurons, but these 
populations of neurons were indistinguishable by our analyses. 
 Inhibitory neurons exert complex control over excitatory cell firing, both because of their 
exuberant connectivity (in cortex, a single interneuron can contact more than half of the local 
pyramidal neurons) and because of the diverse effects they have on neuronal spiking, depending 
on the location of the synaptic connections (axon initial segment, distal dendrites, soma, etc).38 
Therefore, even a small change in the magnitude of connectivity could have profound effects on 
network excitability and precision. We found that although neither expression of the GABA 
synthesizing enzymes, GAD1 and GAD2, nor amplitude and interevent interval of mIPSCs was 
changed by patient CSF treatment, GABAergic synapse density onto excitatory neurons was 
decreased. We suspect this difference in results between the electrophysiology and staining 
experiments was due to the increased power of immunostaining experiments, which sampled ~30 
neurons per condition, as opposed to the physiology experiments, which measured mIPSCs from 
6 neurons per condition. 
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This was consistent with literature showing that genetic or pharmacological NMDAR 
dysfunction can lead to a loss of inhibitory tone, but indicated a distinct mechanism that may 
contribute in this disease. Although a loss of glutamatergic drive to inhibitory interneurons is often 
considered the pathogenic event leading to disinhibition in NMDAR hypofunction models, our 
data suggested that an additional phenomenon could be the homeostatic down-regulation of 
inhibitory synapses onto excitatory neurons. 
It will be important to extend these findings to an in vivo context to establish the 
pathophysiological mechanisms leading to dysfunction in patients. However, it is interesting to 
consider the implications of engaging homeostatic plasticity mechanisms in the presence of anti-
NMDAR antibodies. Examples of homeostatic responses to altered levels of activity have been 
found or hypothesized to occur in several neurological disorders, including epilepsy, myasthenia 
gravis, Alzheimer’s disease, and schizophrenia.39 In schizophrenia, and NMDAR hypofunction 
models, loss of inhibition may contribute to symptom profile and disease progression. 
Understanding the mechanisms that drive circuit-level changes underlying the behavioral and 
neurological symptoms of the disorder will be important to link the pathophysiologic events of 
anti-NMDAR encephalitis with those of other disorders with similar neuropsychiatric 
manifestations. 
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Figure 1: Patient and commercial GluN1 antibodies were similarly distributed after 
immunostaining.  
(A) Sagittal mouse brain sections immunostained for GluN1 with 2 patient CSF samples (top) or 2 
commercial anti-GluN1 antibodies against C-terminal epitopes (bottom). The pattern of NMDAR 
localization was similar, with the greatest intensity of immunoreactivity in the hippocampus and 
less in cortex, striatum, and cerebellum. Scale bar = 1 mm 
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(B) Cellular localization in hippocampal dentate gyrus neurons stained with patient CSF (left, 
green in overlay) or commercial anti-GluN1 (middle, red in overlay), demonstrating co-labeling of 
NMDAR clusters throughout the neuropil.  Scale bar = 20 µm. 
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Figure 2: Patient antibodies decreased surface NMDARs on excitatory and inhibitory 
hippocampal neurons.  
(A, B) Hippocampal neurons immunostained for surface GluN1, total GluN1, and GAD-6 after 
treatment for 24 hours with control or patient CSF and imaged with confocal microscopy.  A, 
GAD-, excitatory neurons; B, GAD+, inhibitory neurons. Surface NMDARs were defined as the 
colocalization of non-permeabilized patient antibody staining, which recognized an extracellular 
epitope, and permeabilized commercial GluN1 staining, which recognized an intracellular epitope. 
Scale bar = 5 µm. 
(C) Quantification of surface NMDAR density on excitatory, GAD- neurons, and inhibitory, GAD+ 
neurons (n=12-28 cells per condition, 3 independent experiments). Treatment with patient CSF 
caused a similar, significant reduction in surface NMDAR clusters on both excitatory and 
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inhibitory neurons compared to control CSF treatment (excitatory, 27.97±2.67 versus 13.71±2.51; 
inhibitory, 26.38±1.96 versus 15.6±1.83).  Asterisk indicates significance; one-way ANOVA, 
p<0.05. 
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Figure 3:  Patient antibodies increased the rate of NMDAR internalization in a time-
dependent and activity-independent manner   
(A) Hippocampal neurons were treated for various lengths of time with patient CSF or F(ab) 
fragments and then immunostained for surface antibody-bound GluN1, internalized antibody-
bound GluN1, and total GluN1.  F(ab) fragments were used to monitor the constitutive, antibody-
independent turnover of NMDARs.  Coverslips were imaged and NMDAR cluster density 
analyzed. Scale bar = 5 µm. 
(B) Quantification of surface and internalized NMDARs following treatment (n=17-55 cells per 
condition).  Surface NMDAR density was significantly decreased after 12 hours of patient CSF 
treatment compared with patient antibody-derived F(ab) fragments (86.02±7.46% versus 
140.2±8.68%), after which surface levels reached a plateau.  This was paralleled by an increase 
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over time in the density of internalized NMDARs (by 12 hours, 72.01±9.67% versus 
17.83±4.26%).  Asterisk indicates significance; one-way ANOVA, p<0.05. 
(C) Hippocampal neurons were treated for 24 hours with control or patient CSF with or without 
APV, then immunostained for surface GluN1, total GluN1, and presynaptic terminal marker 
bassoon. Scale bar = 5 µm. 
(D) Quantification of synaptic NMDAR density (n=12-18 cells per condition, 3 independent 
experiments).  Patient CSF caused a significant reduction in NMDAR density in both the 
presence (46.86±4.17% of control CSF) and absence (52.18±6.19% of control CSF) of APV.  
Asterisk indicates significance; one-way ANOVA, p<0.05. 
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Figure 4:  Patient antibody-bound NMDARs trafficked through recycling endosomes and 
lysosomes.	  
(A) Hippocampal neurons were treated with one of the following:  F(ab) fragments generated from 
patient antibodies, patient CSF (full IgG), F(ab) plus NMDA and glycine, or F(ab) plus picrotoxin.  
Neurons were then immunostained for internalized antibody-bound GluN1, Rab11 (to mark 
recycling endosomes), and Lamp1 (to mark lysosomes). Scale bar = 5 µm. 
(B) Quantification of intracellular trafficking of NMDARs following treatment (n=15-19 cells per 
condition, 3 independent experiments). Left, quantification of internalized NMDAR clusters 
following treatment; middle, quantification of internalized NMDAR clusters colocalized with 
recycling endosome marker Rab11; right, quantification of internalized NMDAR clusters 
colocalized with lysosome marker Lamp1. After 24 hours, there was a significant increase in 
internalized NMDAR cluster density following treatment with patient CSF, F(ab) plus NMDA and 
glycine, and F(ab) plus picrotoxin compared with F(ab) fragments alone (5.26±0.45, 5.40±1.31, 
6.15±1.03 versus 0.68±0.17; p<0.05). Asterisk indicates significance; one-way ANOVA, p<0.05.  
There were no significant differences in the intracellular localization of NMDARs between the 
three treatments used to induce internalization (recycling endosomes: 29.56±4.54%, 
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32.46±4.37%, 47.83±6.01%; lysosomes: 12.03±2.80%, 10.16±2.25%, 17.21±8.12%). One- way 
ANOVA, p>0.05.    
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Figure 5: Patient antibodies did not acutely antagonize the NMDAR 
(A) Representative traces of AMPAR- and NMDAR-mediated miniature excitatory postsynaptic 
currents (mEPSCs) from whole-cell patch-clamp recordings of hippocampal neurons following 
treatment with control or patient CSF for 30 minutes or F(ab) fragments for 24 hours.  Recordings 
were made in the presence of TTX, picrotoxin, and 0 mM Mg2+ to isolate dual glutamatergic 
currents.  In the lower traces, APV was added to block the NMDAR-mediated portion of the 
mEPSC.   
(B) Representative averaged NMDAR-mediated mEPSCs recorded from neurons in different 
treatment conditions.  The difference between the 0 mM Mg2+ condition and the 0 mM Mg2+ plus 
APV condition is plotted, showing the NMDAR current.   
(C) Quantification of NMDAR current amplitude following treatment (n=5-10 cells per condition).  
Amplitude was not significantly different (2.14±0.62 pA, control CSF; 1.26±0.34 pA, patient CSF; 
1.79±0.55 pA, F(ab) fragments).  One-way ANOVA, p>0.05.   
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Figure 6: Patient antibodies were directly pathogenic.  
(A) IgGs were removed from patient CSF with protein A- and protein G-agarose beads. 
Hippocampal neurons were immunostained with control CSF, patient CSF or IgG-depleted CSF. 
Similar to control CSF, depleted CSF did not stain neurons.  Scale bar = 20 µm. 
(B) Hippocampal neurons were treated for 24 hours with control CSF, patient CSF, or depleted 
CSF, then immunostained for surface GluN1, total GluN1, and bassoon.  Scale bar = 5 µm. 
(C) Quantification of synaptic NMDAR density following treatment (n=19-21 cells per condition, 3 
independent experiments). Depletion of IgG from patient CSF abrogated the reduction in synaptic 
NMDAR cluster density (depleted CSF, 99.15±6.47% of control CSF; patient CSF, 57.70±7.10% 
of control CSF).  Asterisk indicates significance; one-way ANOVA, p<0.05.  
 
 
62	  
Figure 7: Patient antibodies caused a homeostatic decrease of inhibitory synapse density  
(A) Hippocampal neurons were treated for 24 hours with control CSF, patient CSF, or APV, then 
immunostained for surface GluN1, total GluN1, and bassoon. Scale bar = 5 µm. 
(B) Quantification of synaptic NMDAR density following treatment (n=18-20 cell per condition, 3 
independent experiments).  Patient CSF caused a significant decrease in cluster density 
(43.27±4.48 % of control CSF), while APV caused a significant increase (160.4±12.69 % of 
control CSF).  Asterisk indicates significance; one-way ANOVA, p<0.05.   
(C) Representative traces of GABAAR-mediated miniature inhibitory postsynaptic currents 
(mIPSCs) from whole-cell patch-clamp recordings of hippocampal neurons following treatment 
with control or patient CSF for 24 hours.  Recordings were made in the presence of TTX, CNQX, 
and APV.  
(D) Quantification of mIPSC amplitude and inter-event interval following treatment (n=5-6 cells 
per condition).  Amplitude (45.49±6.97 pA, control CSF; 40.74±3.43, patient CSF) and inter-event 
interval (1734±474.1 ms, control CSF; 1139±154.3 ms, patient CSF) were not significantly 
different.  Mann-Whitney test, p>0.05. 
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(E) Hippocampal neurons were treated with control or patient CSF for 24 hours, then 
immunostained for GABAAR and vGAT. Scale bar = 5 µm. 
(F) Quantification of inhibitory synapse density onto excitatory neurons following treatment (n=30 
cells per condition, 3 independent experiments).  Patient CSF caused a significant decrease in 
inhibitory synapse density (87.52±3.00% of control treatment).  Asterisk indicates significance; 
Mann-Whitney test, p<0.05.  
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Abstract  
Objective: Autoimmune mediated anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor (AMPAR) encephalitis is a severe but treatment-responsive disorder with prominent 
short-term memory loss and seizures. The mechanisms by which patient antibodies affect 
synapses and neurons leading to symptoms are poorly understood.  
Methods: The effects of patient antibodies on cultures of live rat hippocampal neurons 
were determined with immunostaining, Western blot and electrophysiological analyses. 
Results: We show that patient antibodies cause a selective decrease in the total surface 
amount and synaptic localization of GluA1- and GluA2-containing AMPARs, regardless of 
receptor subunit binding specificity, through increased internalization and degradation of surface 
AMPAR clusters. In contrast, patient antibodies do not alter the density of excitatory synapses, N-
methyl-D-aspartate receptor (NMDAR) clusters or cell viability. Commercially available AMPAR 
antibodies directed against extracellular epitopes do not result in a loss of surface and synaptic 
receptor clusters, suggesting specific effects of patient antibodies. Whole-cell patch clamp 
recordings of spontaneous miniature postsynaptic currents show that patient antibodies decrease 
AMPAR-mediated currents, but not NMDAR-mediated currents. Interestingly, several functional 
properties of neurons are also altered: inhibitory synaptic currents and vGAT staining intensity 
decrease, while the intrinsic excitability of neurons and short interval firing increase.	   
Interpretation: These results establish that antibodies from patients with anti-AMPAR 
encephalitis selectively eliminate surface and synaptic AMPARs, resulting in a homeostatic 
decrease in inhibitory synaptic transmission and increased intrinsic excitability, which may 
contribute to the memory deficits and epilepsy that are prominent in patients with this disorder. 
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Introduction 
There are several recently identified paraneoplastic autoimmune encephalitides in which 
patients develop autoantibodies against cell surface and synaptic proteins,1,2 including NMDARs 
(Dalmau et al., 2007; Dalmau et al., 2008) and AMPARs.3 Patients with anti-AMPAR encephalitis 
have anti-GluA1 and/or anti-GluA2 antibodies in serum as well as cerebrospinal fluid (CSF). 
These patients mainly present with limbic dysfunction including confusion, agitation, seizures, and 
severe short-term memory deficits, which recover with interventions to reduce antibody titer. In 
spite of effective treatments, there is a high rate of relapse,3 and the cellular and synaptic 
mechanisms that underlie these syndromes are largely unknown. AMPARs are heterotetramers 
composed of a combination of subunits, GluA1-4, that are expressed in a region-specific 
manner4–8 and mediate most of the fast excitatory synaptic transmission in the brain.9 Though 
AMPARs are widely expressed throughout the central nervous system, GluA1/2 and GluA2/3 
levels are exceptionally high in the hippocampus and other limbic regions,10 similar to the 
distribution of immunoreactivity with patient antibodies.3 AMPARs are essential for basal 
excitatory transmission as well as expression of long-term potentiation,11–13 a process linked to 
memory formation. Our previous studies showed that patient antibodies caused a decrease in the 
synaptic localization of AMPAR clusters.3 However, how patient antibodies alter synaptic and 
neuronal function underlying patients’ symptoms is poorly understood. Moreover, genetic 
manipulations eliminating individual AMPAR subunit expression and thus function result in only 
limited deficits in memory tasks,11,12,14 inconsistent with the complete loss of short-term memory 
seen in patients. Recent work suggests that the total surface expression of AMPAR proteins, 
regardless of subunit type, is important for LTP expression.13 Whether patient antibodies cause a 
decrease of surface AMPAR protein is not known. 
Here we report that patient anti-AMPAR antibodies decrease surface protein level and 
synaptic localization of AMPARs, regardless of receptor subunit binding specificity, without 
dismantling excitatory synapses. Interestingly, the loss of AMPAR-mediated synaptic 
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transmission results in a compensatory decrease of inhibitory synaptic transmission and an 
increase in intrinsic excitability. 
Together, these changes may contribute to the loss of memory and seizures that are 
hallmarks of this disorder in patients. 
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Materials and Methods 
Cell culture and patient antibody treatment 
Primary rat hippocampal neuron and astrocyte co-cultures were prepared from embryonic day 18-
19 as previously described.15,16 Patient or control CSF was collected and filtered using Millex 
filters (Millipore). High-titer CSF was diluted 1:20-100 to treat neurons in vitro for 24 hours or as 
stated. Immunoglobulin G (IgG) from one patient’s (02-066) serum was collected and filtered 
using protein A/G sepharose columns as described.16 Treatment with patient IgG (~20 µg/ml) or 
serum (1:200 dilution) decreased synaptic AMPAR clusters to a similar extent as treatment with 
CSF (see Results), without side effects to culture health. Patient CSF was used to treat neurons 
unless otherwise stated. In surface biotinylation experiments, control or patient sera were used to 
treat neurons (1:200 dilution). Each CSF was tested for antibody reactivity by staining mouse or 
rat brain sections and HEK cells expressing GluA1/GluA2 heteromers of the AMPAR as 
previously described.3 
 
Patient samples 
Control patients were from a previously described tissue bank (Lai et al., 2009): 07-238, 09-724, 
09-726. All patients had idiopathic non-inflammatory neuropsychiatric symptoms, without 
autoantibodies in serum and CSF. Anti-AMPAR encephalitis patients: 04-067, 02-066, 09-276. 
Case 04-067 is patient #1, Case 02-066 is patient #2 described in previously published work.3 
Case 04-067 is GluA1 positive, GluA2 and GluA3 negative; Case 02-066 is GluA2 positive, GluA1 
and GluA3 negative. Case 09-276 (not previously reported) is GluA1 positive, GluA2 and GluA3 
negative. This patient is a 46 year-old woman who 4 years ago developed a clinical picture of 
typical paraneoplastic limbic encephalitis associated with breast cancer. She was treated with 
tumor resection, immunotherapy and chemotherapy and had a remarkable response to treatment. 
She is back to work, although has mild residual memory problems.	  Table 1 shows the usage of 
patient samples in experiments. 
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Biotinylation of surface proteins and analysis by western blot 
Neurons were treated with patient serum with anti-GluA1 or anti-GluA2 antibodies for 1 day. 
Procedures for total, intracellular, and surface protein collection were performed as described 
previously.16 Briefly, neuron cultures were washed with PBS-based rinsing buffer and incubated 
for 30 min at 4°C with 1 mg/ml Sulfo-NHS-Biotin (Thermo Fisher Scientific) in rinsing buffer. 
Neurons were then lysed in RIPA buffer (150mM NaCl, 1mM EDTA, 100mM Tris-HCl, 1% Triton 
X-100, 1% sodium deoxycholate, 0.1% SDS, pH=7.4), supplemented with 1:500 protease 
inhibitor mixture III (Calbiochem) at 4°C for 1 h. Lysates were cleared of debris by centrifugation 
at 12,4000g for 20 minutes. An aliquot of the supernatant was taken for the total protein, and a 
second aliquot was incubated with avidin-linked agarose beads (Immobilized Monomeric Avidin; 
Thermo Fisher Scientific) overnight at 4°C to absorb surface fraction. After centrifugation, the 
supernatant was removed for the intracellular fraction. The beads were subsequently washed and 
eluted for surface protein. Protein samples were separated on 4-15% SDS-PAGE gel and 
transferred to nitrocellulose membranes. Surface fractions were probed with antibodies against 
GluN1 (rabbit, 1:1000, Chemicon AB1516; replaced by Millipore AB9864, similar results obtained 
with both), GluA1 (rabbit, 1:200, Millipore AB1504), GluA2/3 (rabbit, 1:200, Chemicon AB1506), 
Stargazin (rabbit, 1:500, Millipore AB9876), GABAB1Rs (guinea pig, 1:200, Millipore AB2256), 
GABAARβ2/3 (mouse, 1:200, Millipore 05-474), vGAT (guinea pig, 1:1000, Synaptic Systems 
131-004), and β-actin (chicken, 1:1000, Abcam ab13822). Intracellular fractions were used to 
probe for intracellular GluA1, GluA2/3, actin and vGAT. Total lysate protein fractions were used to 
probe for total GluA1. MAP2, actin and GABAARs were used as loading controls for intracellular, 
total and surface fractions, respectively. Blots were incubated with alkaline phosphatase (AP)-
conjugated goat anti-mouse or goat anti-rabbit secondary antibodies (1:3000, Cell Signaling), and 
signals were visualized using Western-Star chemiluminescent detection system (Applied 
Biosystems). All quantified images were in the linear exposure range, were digitally scanned in 
ChemiDoc™ XRS+System (Bio-Rad) and signals quantified using Image Lab™ software (Bio-
Rad). 
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Whole cell electrophysiological recordings 
Whole-cell voltage clamp recordings were performed from 17–21 div hippocampal pyramidal 
neurons at room temperature (22-25°C), using a HEKA EPC 10 patch clamp amplifier and 
Patchmaster multi-channel data acquisition software. Briefly, neurons were incubated in 
extracellular physiology solution (in mM): for miniature excitatory or inhibitory postsynaptic 
currents (mEPSCs or mIPSCs), recordings were performed in 119 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 
30 glucose, 10 HEPES, pH=7.4; NMDAR-mediated mEPSCs recordings were performed with 0 
MgCl2 and 1 glycine; action potential recordings were performed in 140 NaCl, 3 KCl, 0.6 MgCl2, 
2.5 CaCl2, 10 HEPES, 10 glucose. Voltage-clamp recordings were made using borosilicate glass 
microelectrodes (resistance 4-6 MΩ) filled with intracellular solution (in mM): mEPSCs recording 
was performed with 100 cesium gluconate, 0.2 EGTA, 5 MgCl2, 2 ATP, 0.3 GTP, 40 HEPES, 
pH=7.2; mIPSCs and action potential recording were performed with 140 KCl, 2 MgCl2, 11 EGTA, 
10 HEPES, 7 glucose, pH=7.3. mEPSCs and mIPSCs were recorded at -70 mV in the presence 
of combinations of the following drugs to isolate desired currents: TTX (1 µM), Picrotoxin (10 µM), 
APV (50 µM) and CNQX (10 µM). Action potentials were recorded in current clamp mode. Pipette 
voltage offset was neutralized before the formation of a gigaohm seal. Membrane resistance, 
series resistance, and membrane capacitance were determined from current transients elicited by 
a 5 mV depolarizing step from a holding potential of -80 mV, using the whole-cell application of 
Patchmaster software. Criteria for cell inclusion in the data set included a series resistance ≤30 
MΩ and stability throughout the recording period. Currents were amplified, and sampled at 20 
kHz, then miniature current recording traces were digitally low-pass filtered at 2.5 kHz and events 
were detected and analyzed using MiniAnalysis (Synaptosoft, Leonia, NY). 
 
Immunostaining for surface AMPARs, pre- and postsynaptic components 
To stain surface AMPAR clusters, control or treated neurons were washed in culture media and 
were incubated with commercial anti-GluA1 (rabbit, 1:10, Calbiochem PC246; immunogen is a 
synthetic peptide (RTSDSRDHTRVDWKR) corresponding to amino acids 271-285 of rat GluA1), 
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or anti-GluA2 (1:500, Millipore MAB397; immunogen is recombinant fusion protein with putative 
N-terminal portion of GluA2 from AA 175-430) antibodies directed against an extracellular epitope 
for 30 minutes, washed and incubated with appropriate fluorescently conjugated secondary 
antibodies for 30 minutes, and washed in PBS. Neurons were then fixed in 4% 
paraformaldehyde/sucrose in PBS for 15 minutes, permeabilized with cold 0.25% Triton X-100 for 
5 minutes, and blocked in 5% normal goat serum (Invitrogen) for 1 hour at room temperature. 
Additional immunostaining was performed with various combinations of primary antibodies: anti-
GluN1 (rabbit, 1:1000, Chemicon AB1516; replaced by Millipore AB9864, similar results obtained 
with both), anti-GluA1 against an intracellular epitope (rabbit, 1:200, Millipore AB1504), anti-
GluA2/3 (rabbit, 1:100, Millipore AB1506), anti-PSD-95 (mouse, 1:500, Fisher Thermo Scientific 
MA1-045), anti-Stargazin (rabbit, 1:500, Chemicon AB9876), anti-SV2 (mouse, 1:200, 
Developmental Studies Hybridoma Bank), anti-VGLUT1 (guinea pig, 1:5000, Chemicon AB5905). 
Antibodies were visualized after staining with the appropriate fluorescently conjugated secondary 
antibodies (1:200, Jackson ImmunoResearch or Invitrogen). To pulse label surface AMPAR and 
chase the subsequent internalization, neurons were incubated with commercial anti-GluA1 
(rabbit, 1:100, Calbiochem) antibodies for 2 hours. This antibody does not induce significant 
reduction of surface AMPARs (Fig 4). After 2 hours, unbound antibodies were washed off and 
neurons were treated with control or patient CSF for 24 hours. Remaining surface AMPARs were 
labeled live with conjugated secondary antibodies. In experiments measuring internalized 
AMPAR clusters, remaining surface AMPAR epitopes were pre-blocked by non-fluorescence anti-
rabbit secondary antibodies (0.2mg/ml, Jackson ImmunoResearch).17 After fixation and 
permeabilization, internalized AMPARs were visualized by applying fluorescently conjugated 
secondary antibodies.  
 
Confocal imaging, image analysis and statistical analysis  
Randomly selected hippocampal pyramidal neurons, identified by morphology (Hughes et al., 
2010; Peng et al., 2012) were confocally imaged (Leica TCS 4D system). Images were 
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thresholded automatically using an iterative thresholding technique (Bergsman et al., 2006), and 
the number and area of individual immunostained pre- or postsynaptic clusters were determined 
using interactive software (custom-written ImageJ macros). Clusters with pixel overlap of pre- and 
postsynaptic markers were considered colocalized and thus synaptic. Cluster density was 
compared among conditions using the Kruskal-Wallis nonparametric ANOVA test followed by 
Dunn’s pairwise multiple comparison test, unless otherwise indicated. All values are presented as 
mean ± s.e.m. 
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Results 
Patient anti-GluA1 or GluA2 antibodies decrease surface AMPAR protein and synaptic 
localization 
Previous work showed that anti-AMPAR encephalitis patients had antibodies against 
GluA1 and GluA2 in their CSF.3 Since some patients with autoimmune encephalitis had 
antibodies against multiple antigens,3,18 we selected patients with only GluA1 or GluA2 antibodies 
in order to eliminate effects from other antibodies. To further confirm the specificity of antibody 
binding, we incubated patient CSF with control human embryonic kidney (HEK) 293 cells or cells 
expressing GluA1/GluA2-containing AMPARs to deplete these specific antibodies. The control 
depleted patient CSF still stained neuronal surface AMPAR clusters as previously reported3 while 
patient CSF depleted by incubation with GluA1/GluA2 expressing HEK cells showed little 
immunostaining (Fig 1A). This result confirms that patient antibodies in CSF samples are 
predominantly anti-GluA1/GluA2 antibodies.	  	  
Previous work showed that the antibodies from a single patient with anti-AMPAR 
encephalitis selectively decreased synaptic AMPAR clusters, and after antibody removal, AMPAR 
clusters density recovered back to control levels.3 Patients with anti-AMPAR encephalitis could 
be subdivided into two groups depending on the specificity of the antibodies present in the patient 
CSF (GluA1 or GluA2). Previous studies knocking out the expression of GluA1 or GluA2 AMPAR 
subunits suggested that there could be compensatory expression of the other remaining 
subunits.11,12,14 We investigated whether patient anti-GluA1 or anti-GluA2 antibodies had similar 
effects on the localization of AMPAR subunits. Specifically, we assessed whether anti-GluA1 
patient antibodies affected just GluA1-containing AMPARs or both GluA1 and GluA2-containing 
AMPARs. Hippocampal neurons were incubated for 1-3 days with patient CSF containing anti-
GluA1 or anti-GluA2 antibodies, followed by immunocytochemical analyses of synaptic and 
surface GluA1 or GluA2/3 clusters. 
Patient anti-GluA1 and anti-GluA2 antibodies significantly decreased both GluA1- and 
GluA2/3-containing synaptic AMPAR cluster density (Fig 1B, C). Similar results were obtained 
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using purified IgG prepared from the same patient samples, suggesting that the patient antibodies 
alone caused the decrease of synaptic AMPAR cluster density. In addition, patient antibodies 
also decreased the size and fluorescence intensity of AMPAR clusters (Fig 1D), suggesting that 
antibodies also cause de-clustering. Furthermore, surface biotinylation followed by western blot 
analysis of GluA1 or GluA2 subunits showed a decrease of surface protein levels of both GluA1 
and GluA2, treated by either anti-GluA1 or anti-GluA2 patient CSF (Fig 1F, G), compared to CSF 
from control patients. Western blots from treated and control neurons showed that the amount of 
intracellular AMPARs was not different and thus the total amount of AMPARs decreased (Fig 1F, 
G), consistent with degradation of internalized receptors (see Fig 3). However, there was neither 
a significant compensatory increase in GluA2/3-containing receptors within synapses (Fig 1B-E), 
nor of surface or intracellular GluA2/3 protein levels (Fig 1F, G) when treated with anti-GluA1 
patient antibodies or vice versa. These data suggest that patient antibodies directed against 
either subunit have similar effects on GluA1- and GluA2-containing AMPARs, the main subunits 
comprising AMPARs in hippocampus.6,10 
 
Patient antibodies do not alter glutamatergic synapse density and cell viability 
Because AMPARs interact with many other synaptic proteins and are major components 
of mature synapses,8,19 we examined whether patient anti-AMPAR antibodies also affected 
excitatory synapse density and/or the density of other postsynaptic components. Hippocampal 
neurons were cultured with CSF or serum containing anti-GluA1 or anti-GluA2 antibodies for 1-3 
days, followed by immunostaining or western blot analyses of synaptic proteins, including 
presynaptic vesicular glutamate transporter (vGlut), postsynaptic PSD-95, the AMPAR interacting 
protein Stargazin,20,21 the NMDAR obligate subunit GluN1, inhibitory GABAA receptor (GABAAR) 
and GABAB1 receptors (GABAB1R). Patient antibodies did not alter the density of excitatory 
synapses (Fig 2C), presynaptic vGlut clusters, postsynaptic PSD-95, GluN1 or Stargazin clusters, 
compared to control CSF (Fig 2A, C, D), or the amount of surface GluN1, Stargazin or GABAB1R 
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protein (Fig 2B, E). These data suggest that patient anti-AMPAR antibodies do not significantly 
alter the major components of synapses.	  	  
To examine whether the patient antibodies affected neuronal viability, the density of 
neurons on coverslips was assayed by staining with DAPI and microtubule associated protein 2 
(MAP2) to label nuclei and neuronal dendritic arbors, respectively. After 24 hours of treatment, 
the density of neurons treated with patient CSF was comparable with the density in control or 
untreated conditions (Fig 2F), suggesting that patient anti-AMPAR antibodies did not cause 
significant neuronal loss. Consistently, the percentage of TUNEL-positive apoptotic neurons was 
very low (<1%) in all conditions (Fig 2G), suggesting that patient anti-AMPAR antibodies did not 
induce significant neuronal apoptosis. This is consistent with the lack of significant neuronal loss 
and frequently observed patient recovery to pre-disease baseline.3 
Together, our data suggests that the loss of surface and synaptic localization caused by 
patient antibodies was specific to AMPARs, without widespread effects on most other synaptic 
components or neuronal viability. 
 
Patient antibodies increase the net internalization of AMPAR clusters 
The decrease of synaptic AMPARs following patient antibody treatment was 
accompanied by the appearance of AMPAR-positive clusters that were non-synaptic (Fig 1A, 
green GluA1 or GluA2 clusters that were not colocalized with red PSD-95 clusters in patient 
antibody treatment, compared to yellow clusters in control treatment). To determine whether the 
reduction of surface AMPARs resulted from receptor internalization, surface AMPARs were 
labeled by a commercial anti-GluA1 antibody (comGluA1), followed by treatment with control or 
patient CSF for 1, 4 and 24 hours. 
Control treated neurons showed a decrease of surface GluA1 AMPARs by 24 hours (Fig 
3A, C). This suggested that under basal conditions, GluA1-containing AMPARs undergo a 
relatively slow rate of turnover. In contrast, neurons treated with patient CSF showed a 
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significantly decreased surface cluster density by 24 hours (Fig 3A, C). This suggests that patient 
anti-AMPAR antibodies cause a rapid internalization of surface AMPARs. 
To specifically quantify internalized AMPARs, neurons were pre-treated with an excess of 
unconjugated secondary antibodies (Fig 3A, bottom image shows effectiveness of pre-blockade). 
The total number of internal GluA1-containing AMPARs decreased in control treated neurons 
over time, but increased in neurons treated with patient antibodies at 1 hour and 4 hours, 
consistent with induced internalization of AMPARs (Fig 3B, D). By 24 hours, internal GluA1 
clusters were low in both conditions (Fig 3B, D), indicating that pre-labeled AMPARs underwent 
degradation rapidly. These data suggest that patient anti-AMPAR antibodies increase the net 
AMPAR internalization rate, and this loss of surface AMPARs is accompanied by transient 
accumulation of internalized AMPARs. 
Previous studies suggest internalized AMPARs are targeted to the early endosome, then 
either recycled back to the surface, or transferred to late endosome and lysosome for 
degradation.17 In order to examine the compartmentalization of AMPAR clusters internalized by 
patient antibodies, neurons were treated for 4 hours, a time point when internalized AMPARs 
were ample, then stained for intracellular patient antibodies as well as early endosome (EEA1), 
late endosome/lysosome (Lamp1), or recycling endosome (transferrin receptor, TrfR) markers 
(Fig 3E, green indicates intracellular AMPARs labeled by patient antibodies, red indicates cell 
compartment marker). A small percentage of intracellular patient antibody-bound AMPARs were 
colocalized with the early endosome marker EEA1 or recycling endosome marker TrfR in 
dendrites and cell bodies (Fig 3E, F). In contrast, in the cell body, 42±5% of these intracellular 
AMPAR clusters were colocalized with the lysosome marker Lamp1. A similar colocalization of 
intracellular AMPAR clusters with Lamp1 was observed in cells treated with control CSF (data not 
shown). 
These results suggest that patient antibodies increase the net internalization rate of 
surface AMPARs and that internalized AMPARs are degraded in lysosomes. 
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Commercial anti-AMPAR antibodies do not result in receptor internalization 
We next examined whether commercially available anti-AMPAR antibodies have similar 
effects on synaptic AMPAR clusters. After 1 day of treatment with a commercial anti-GluA1 
antibody or anti-GluA2 antibody, the synaptic localization of AMPAR clusters was unchanged 
across a wide range of antibody concentrations (Fig 4B). When the GluA1 antibody concentration 
was high (dilution 1:20, 1:50), AMPAR cluster staining increased, most likely due to an increased 
association of commercial antibodies with surface receptors in the absence of increased 
internalization (Fig 4C; treatment with GluA1 at 1:50 dilution does not increase AMPAR 
internalization). Interestingly, when a secondary antibody was included to cross-link the primary 
antibody in neurons treated with anti-GluA2 antibodies, a significant decrease of synaptic AMPAR 
cluster density was observed (Fig 4A, 4B). 
To further confirm that treatment with commercial GluA2 antibodies plus secondary 
increased net internalization of AMPARs while decreasing synaptic AMPARs, as observed with 
patient antibodies, we examined the amount of internalized AMPARs. Neurons pre-labeled with 
GluA1 antibodies were treated with commercial GluA1 antibodies, GluA2 antibodies with or 
without secondary antibody or with patient CSF (Fig 4C). The patient CSF treated neurons had 
the highest density of internalized AMPAR clusters, but commercial GluA2 plus secondary treated 
neurons also had a significantly higher density of internalized AMPARs compared to baseline 
levels. Neurons treated with commercial GluA1 or GluA2 antibodies alone did not show increased 
accumulation of internalized AMPARs over 4 hours. These results suggest that some 
commercially available primary-plus-secondary antibody complexes have a similar but less potent 
effect on internalization of surface AMPARs as patient antibodies, while commercial anti-GluA 
antibodies alone do not alter surface receptor localization. 
 
Patient antibodies decrease AMPAR- but not NMDAR-mediated synaptic transmission 
To determine whether patient antibodies reduce AMPAR-mediated synaptic transmission, 
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AMPAR-mediated miniature excitatory postsynaptic currents (mEPSCs) were measured using 
whole cell voltage clamp recordings from neurons treated with patient (anti-GluA1 or anti-GluA2) 
or control CSF for 24 hours. Recordings were carried out in the presence of TTX, picrotoxin and 
APV to block action potentials, GABAAR-mediated inhibitory currents and NMDAR-mediated 
currents, respectively. 
In neurons treated with control CSF, frequent AMPAR-mediated mEPSCs were observed 
(Fig 5A, C, D). In contrast, the AMPAR-mediated mEPSCs in neurons treated with anti-GluA2 
patient CSF were significantly smaller and less frequent. Thus, the anti-GluA2 patient antibodies 
caused a significant decrease in mEPSC amplitude and frequency compared to controls, and this 
was consistent with another recent report.22 This decrease was also evident by 4 hours after 
treatment (Fig 5C, D), consistent with immunostaining data demonstrating significant antibody- 
mediated receptor internalization at this time point. Similar results were observed for anti-GluA1 
patient antibody treated neurons. These results suggest that patient anti-GluA1 and anti-GluA2 
antibodies decrease the amplitude and frequency of AMPAR-mediated mEPSCs in hippocampal 
neurons.	  	  
To determine whether the effect of patient antibodies on synaptic currents is specific to 
AMPARs, NMDAR-mediated currents were also measured. To measure these independently of 
AMPAR-mediated mEPSCs, recordings were carried out in presence of TTX, picrotoxin, CNQX 
(an AMPAR blocker), and glycine to reveal all functional NMDARs.23 The amplitude, frequency 
and decay time of NMDAR-mediated currents, which can be blocked by APV (Fig 5B, bottom 
trace), were not significantly different in neurons treated with control or patient CSF (Fig 5B, E, F, 
G). This result suggests that the patient antibodies specifically eliminate AMPAR function. Since 
excitatory synapse density along dendrites assayed by immunostaining (Fig 2) was not altered, 
the proportion of silent synapses without AMPARs was increased. In addition, the observation 
that the frequency of NMDAR-mediated currents was not affected also suggests that 
glutamatergic presynaptic release probability is unlikely to be altered by patient antibodies. 
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These results show that patient antibodies specifically decrease synaptic AMPAR-
mediated currents and not NMDAR-mediated currents, consistent with the specific loss of 
surface, synaptically localized AMPAR clusters. The functional effect of antibody-mediated 
AMPAR internalization is a weakening of glutamatergic synaptic transmission. 
 
Compensatory decrease in inhibition in neurons treated with patient antibodies 
Previous studies showed that chronic pharmacological blockade of AMPAR-mediated 
transmission led to a homeostatic decrease of inhibitory synapse strength such that neurons 
maintain their firing rate.24–28 In order to examine whether similar compensatory changes 
occurred following the decrease in AMPAR-mediated transmission induced by patient antibodies, 
miniature inhibitory postsynaptic currents (mIPSCs) were recorded in the presence of TTX, APV 
and CNQX. Measurements were done 48 hours after patient CSF treatment, and the decrease of 
synaptic AMPARs assayed by immunostaining were comparable to 24 hours treatment. The 
frequency of mIPSCs decreased significantly (Fig 6A-C) while the amplitude was comparable 
between control and patient antibody treated conditions. To examine the effects of patient 
antibodies on inhibitory synapses, neurons were immunostained with an inhibitory presynaptic 
marker, vesicular GABA transporter (vGAT), and the postsynaptic GABAARβ2/3 (Fig 6D). Patient 
CSF or CNQX treatment for 48 hours reduced vGAT staining intensity (Fig 6D, F), while the 
density of inhibitory synapses defined by colocalization of vGAT and GABAAR clusters was 
comparable among conditions. In order to confirm that the change of vGAT staining intensity was 
not a direct result of patient antibodies but rather a reflection of decreased neuronal excitation, 
coverslips were treated with KCl to depolarize neurons, increasing their activity, with or without 
patient CSF. In conditions with KCl alone or KCl plus patient CSF, presynaptic vGAT cluster 
intensity was increased significantly (Fig 6D, F), suggesting that changes in inhibitory tone were 
determined by the level of neuronal excitation. Together these results suggest that neurons 
homeostatically decrease inhibitory synaptic strength in response to the reduction in AMPAR-
mediated synaptic transmission. 
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Patient antibodies cause homeostatic increase of intrinsic excitability and altered action potential 
firing 
Previous work showed intrinsic neuronal properties are also affected by homeostatic 
scaling.29 Thus we examined the effect of patient anti-AMPAR antibodies on intrinsic neuronal 
excitability in the presence of APV, CNQX, and PTX to block synaptic transmission. Neurons 
rarely spontaneously fire action potentials under such conditions (Fig 7A, control 0 pA) since all 
synaptic inputs are blocked, but fire upon current injection (Fig 7A). Neuronal excitability was 
greatly increased after 48 hours of treatment with patient CSF. Neurons fired more action 
potentials in response to the same amplitude of current injection (Fig 7A, B), and also fired action 
potentials spontaneously (Fig 7B). After treatment with patient antibodies, input resistance was 
increased (Fig 7C) while resting potential was not significantly altered (data not shown). These 
results suggest that after treatment with patient anti-AMPAR antibodies, neurons are more 
excitable, and tend to fire spontaneously without excitatory input. 
In the absence of synaptic blockers, neurons treated with patient antibodies had a similar 
average firing rate as control neurons (Fig 7E). The fidelity of firing rate was consistent with 
previous observations that average firing frequency was usually maintained after blocking 
excitatory synaptic transmission.29–31 However, while average firing rate was unaffected by 
patient antibodies, the pattern of firing was substantially altered. The inter-spike intervals of 
neurons treated with patient CSF were significantly different from control neurons (Fig 7D, F). 
Specifically, the percentage of spikes with extremely short inter-spike intervals (<10 ms) was 
significantly increased in patient antibody treated neurons compared to controls (Fig 7G). These 
results suggest that patient antibody-mediated reduction of surface AMPARs results in significant 
changes in patterns of action potential firing in hippocampal pyramidal neurons. 
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Discussion 
We examined the effects of autoantibodies from anti-AMPAR encephalitis patients on 
hippocampal neurons. Patient AMPAR antibodies cause a selective decrease in the surface 
amount and synaptic localization of AMPARs, due to increased internalization of AMPARs. 
Consistent with this, patient antibodies caused a decrease in AMPAR- but not NMDAR-mediated 
excitatory postsynaptic currents. While the average action potential firing frequency was 
unaffected, loss of surface AMPARs resulted in significant changes in the pattern of action 
potential firing, likely a result of reduced inhibitory synaptic transmission and an increase in 
intrinsic neuronal excitability. These results demonstrate patient antibodies induced synaptic and 
neuronal changes that may contribute to the short-term memory loss and seizures observed in 
patients with anti-AMPAR encephalitis. 
 
Loss of surface AMPARs and deficits in hippocampal short-term memory 
The phenotypes observed in mice lacking expression of individual AMPAR subunits are 
not conjugate with symptoms observed in patients with anti-AMPAR encephalitis. Spatial learning 
and memory are largely unaffected in GluA1 knockout mice.11 GluA2 knockout mice show 
reduced exploration, impaired motor coordination, abnormal spatial and non-spatial learning but 
enhanced LTP.14,32 These studies suggest that compensatory mechanisms, including expression 
of other AMPAR subunits, may blunt the synaptic, circuit and behavioral effects of loss of a 
particular receptor subunit. A recent study demonstrated that the surface pool of AMPARs is the 
critical determinant of LTP, regardless of subunit types (Granger et al., 2013). This implies that if 
the total surface AMPAR pool was decreased, memory problems would result. Our observation 
that the total surface AMPAR pool is decreased in anti-AMPAR encephalitis regardless of the 
antibody specificity, along with the loss of short-term memory in patients, provides strong support 
for this hypothesis. Our data shows that patient antibodies against either GluA1 or GluA2 have 
similar effects on the density of both GluA1 and GluA2 subunits, without obvious compensation 
from the unaffected subunit. This is probably due to the fact that hippocampal AMPARs are 
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mainly GluA1/GluA2 heteromers (Lu et al., 2009). Once the patient antibodies bind to either 
subunit, they would initiate endocytosis of the entire AMPAR heteromer. Thus this form of 
autoimmune encephalitis provides a unique human model, and informs development of potential 
animal models, for understanding the role of AMPARs in learning and memory. 
Another interesting aspect of anti-AMPAR encephalitis is the recovery process. Patient 
short-term memory can recover after therapeutic intervention to reduce antibody titer. We 
previously showed that after removal of patient antibodies, normal synaptic AMPAR cluster 
density is restored within a few days in cultured neurons.3 Our current study showed that 
inhibitory synaptic transmission and intrinsic neuronal properties were also altered after AMPAR-
mediated synaptic transmission was reduced by treatment with patient antibodies. A number of 
interesting questions remain about whether and how synapses and neuronal circuit properties 
return to their original function during and after recovery. These questions could be explored in 
longitudinal studies of animal models as well as human subjects before and after treatment to 
reduce antibody titer. 
 
Internalization of AMPAR triggered by patient antibodies 
Antibodies trigger cross-linking and internalization of cell surface protein/antigen in single 
cell pathogens,33 blood cells,34 muscle cells in myasthenia gravis,35,36 and neurons in anti-
NMDAR encephalitis.16 Pathogenic antibody induced internalization relies on specific epitopes on 
antigens. Antibodies from several subgroups of patients with anti-NMDAR encephalitis recognize 
a common epitope region based on the tertiary structure of amino acid residues that are remote 
in primary sequence.37 Antibodies from patients with myasthenia gravis also recognize a small 
immunogenic region of nicotinic acetylcholine receptors (AChR).38 Our results show that, in 
contrast to patient antibodies, two commercially available antibodies against the amino-terminal 
domain (ATD)39 of AMPAR subunits do not induce internalization of surface AMPARs. One 
hypothesis is that patient antibodies recognize a specific epitope region, which is not recognized 
by commercial antibodies. Consistent with this hypothesis, anti-AMPAR encephalitis patient 
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antibodies mainly recognize the bottom lobe of the ATD,22 similar to antibodies against the NR1 
subunit of the NMDAR in anti-NMDAR encephalitis.37 In contrast, the peptide sequences used to 
generate the commercial anti-AMPAR antibodies reside in the top lobe of the ATD for the anti-
GluA1 antibody (Calbiochem) and in both lobes for the anti-GluA2 antibody (Millipore). In our 
experiments, the commercial anti-GluA1 did not increase AMPAR internalization, and previous 
studies, which have used this antibody extensively for surface labeling of AMPARs, have not 
reported effects on internalization. Interestingly, the addition of a secondary antibody (as a cross-
linking agent) during anti-GluA2 treatment caused greater receptor internalization. These results 
suggest that enhanced cross-linking of the commercial primary antibody caused increased 
aggregation of the AMPAR-antibody complex resulting in receptor internalization. It is tempting to 
speculate that the differential effects of the commercial antibodies may be a result of the location 
of their epitopes on the AMPAR. Future studies will focus on examining whether specific amino 
acid residues in bottom lobe of the ATD of ionotropic glutamate receptors may be critical for 
autoimmunity. It also remains possible that different antibody isotypes40 give rise to the difference 
in AMPAR internalization, since the patient antibodies are mainly but not exclusively IgG, 
commercial anti-GluA1 is polyclonal IgG, and commercial anti-GluA2 is monoclonal IgG2a. Our 
experiments cannot rule out this possibility. 
 Due to the limited amount of high titer patient CSF and serum samples (2 high titer anti-
AMPAR patient samples sufficient for F(ab) fragment preparation, many fewer than anti-NMDAR 
patient samples available for experiments), we were unable to directly assess the cross-linking 
mediated by patients antibodies as in the previous work.16 Preparing F(ab) fragments exhausts 
large amount of patient samples due to protein loss in the digestion and purification steps. When 
additional high titer patient samples are identified, patient antibody cross-linking of AMPARs can 
be tested directly. 
AMPARs are constantly cycling between the cell membrane and intracellular 
compartments in normal neurons. Surface AMPARs are internalized, entering early endosomes 
and sorting to recycling endosomes or late endosomes/lysosomes over a time course of minutes, 
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depending on previous neuronal activity.17,41 These processes also contribute to long-term 
potentiation and depression,42,43 which are thought to be critical in memory formation. Our results 
showed that surface AMPAR loss was significant after 4 hours, consistent with a significant 
decrease of AMPAR-mediated currents observed around the same time. One hour of patient CSF 
treatment did not cause a significant decrease in surface AMPAR clusters but did cause a 
significant increase of internalized AMPAR cluster density, probably due to the remaining large 
pool of surface AMPARs (high noise compared to signal) but low background from internalized 
AMPAR clusters (low noise compared to signal) for analysis. Our results do not suggest that the 
anti-AMPAR patient antibodies slow normal AMPAR recycling which occurs on a timescale of 
minutes. It is likely that individual AMPARs can be internalized minutes after 
binding with patient antibodies. It is also likely that some of them recycle back to the surface since 
about 10% colocalize with the recycling endosome marker TrfR. Thus the initial imbalance 
between internalization and re-insertion is small. In addition, the binding of patient antibodies with 
AMPARs does not saturate within minutes, but over hours, so the antibodies’ effects within the 
first hour may not be maximal. Together, our results suggest that the balance of internalization 
and reinsertion is disrupted in the presence of patient antibodies, culminating in the accumulation 
of internalized AMPARs that becomes functionally significant after several hours. Our results 
demonstrate that internalized AMPAR-antibody complexes are localized to early endosomes, 
recycling endosomes and lysosomes, especially lysosomes in cell bodies; these are the cellular 
compartments that normally contain constitutively internalized AMPARs.17,41 The observations 
reported here are made after pre-treatment of a population of surface AMPAR for over 2 hours, 
and examining the distribution of these receptors after 4 hours, and thus represent a significantly 
greater period of time than previous studies assaying activity-dependent AMPAR cycling.17,41 Our 
data may reflect a steady-state distribution associated with the extended presence of patient 
antibodies. 
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Homeostatic plasticity associated with surface AMPAR loss caused by patient antibodies 
It is a paradox that a decrease of AMPAR-mediated excitatory transmission could lead to 
seizures in patients. Seizures usually result from an imbalance between excitation and inhibition, 
either via an increase in excitation such as that caused by mutations in voltage-gated sodium 
channels, or a decrease in inhibition such as that caused by GABAAR dysfunction.44–48 An 
exception involving a decrease of AMPAR-mediated synaptic transmission is the Stargazer 
mutant mouse, which develops absence epilepsy due to reduced AMPAR-mediated synaptic 
transmission in inhibitory thalamic reticular nucleus neurons, but not in excitatory relay neurons.49 
None of these previously reported mechanisms can fully explain the seizures in patients with anti-
AMPAR encephalitis. The work we report here suggests that the decrease of excitatory synaptic 
transmission caused by patient antibodies results in a decrease in inhibitory synaptic 
transmission and an increase in intrinsic excitability. These compensatory changes are consistent 
with numerous observations that pyramidal neurons tend to homeostatically maintain firing rate in 
response to chronic inactivity (Turrigiano et al., 1998; Burrone et al., 2002; Turrigiano, 2011). 
Neurons treated with patient anti-AMPAR antibodies maintained a similar overall firing rate as the 
control treated neurons, consistent with homeostatic compensation. However, at this new balance 
point, a neuron might receive less synaptic input from other neurons and fire at a higher intrinsic 
rate, generating epileptic activity. Patient anti-AMPAR antibodies selectively eliminate surface 
and synaptic AMPARs, resulting in a homeostatic decrease in inhibitory synaptic transmission 
and increased intrinsic excitability, which may trigger seizures in patients with this disorder. 
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Figure 1: Patient anti-GluA1 or anti-GluA2 antibodies selectively decrease surface AMPAR 
clusters. 
(A) Hippocampal neurons immunostained with patient antibodies in CSF. Patient CSF was pre-
incubated with control HEK cells, or HEK cells expressing GluA1/GluA2 for 45 minutes, 6 times to 
deplete anti-GluA1/GluA2 antibodies. Control depleted patient CSF shows strong 
immunoreactivity with neuronal surface antigens, GluA1/GluA2 HEK cell depleted patient CSF 
show little immunoreactivity. Scale bar = 10 µm. 
(B) Hippocampal neurons immunostained for GluA1- or GluA2-containing AMPAR clusters and 
postsynaptic PSD-95. Synaptic AMPAR clusters appear yellow due to colocalization of green 
GluA1 or GluA2/3 subunits and red PSD-95. Anti-GluA2 (middle panel) or anti-GluA1 (right panel) 
patient CSF treatment for 24 hours reduced synaptic GluA2 as well as GluA1 cluster density 
without affecting PSD-95 density (n=18-24 neurons from 3 independent experiments). Scale bar 
= 5 µm. 
(C) Quantification of synaptic GluA1 (left plot) or GluA2/3 (right plot) cluster density defined as 
the colocalization between GluA1 or GluA2/3 and PSD-95 clusters per 20 µm dendrite length 
from neurons treated with control, anti-GluA1 or anti-GluA2 patient CSF. The asterisk indicates 
significant difference (compared with control, for synaptic GluA1 clusters, anti-GluA2 patient CSF 
treatment = 60±7%, anti-GluA1 patient CSF treatment = 65±5%; one-way ANOVA, p=0.001; for 
synaptic GluA2 clusters, GluA2 patient CSF treatment = 54±6%, GluA1 patient CSF 
treatment=39±3%; one-way ANOVA, p<0.0001).	  	  
(D) Quantification of GluA1 (left plot) and GluA2/3 (right plot) cluster size (area of individual 
cluster measured in thresholded image) from neurons treated with control, anti-GluA1 or anti-
GluA2 patient CSF. The asterisk indicates significant difference (compared to control, for GluA1 
clusters, anti-GluA2 patient’s CSF treatment = 71±4%, anti-GluA1 patient CSF treatment = 
78±5%; one-way ANOVA, p<0.0001; for synaptic GluA2 clusters, GluA2 patient CSF treatment = 
79±4%, GluA1 patient CSF treatment = 84±7%; one-way ANOVA, p=0.01). 
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(E) Quantification of GluA1 (left plot) and GluA2/3 (right plot) cluster intensity (average pixel 
intensity of individual cluster) from neurons treated with control, anti-GluA1 or anti-GluA2 patient 
CSF. The asterisk indicates significant difference (compared to control GluA1 clusters, anti-GluA1 
patient CSF treatment = 84±5%; one-way ANOVA, p=0.03). 
(F) Western blot analyses of surface biotinylated (upper) and intracellular (bottom) AMPAR 
protein. Patient antibody treatment for 1 day reduces surface and total AMPAR subunits, but not 
intracellular AMPARs. Surface GABAAR and intracellular MAP2 were used as loading controls for 
surface and intracellular fractions, respectively (n=3 independent experiments).  
(G and H) Quantification of band intensity of surface and intracellular AMPAR protein after 
treatment with serum from anti-GluA1 or anti-GluA2 patients, showing a decrease in surface 
GluA1 and GluA2/3 protein in both patient antibody treated neurons compared to control serum-
treated neurons. The asterisk indicates significant difference (surface GluA1 band intensity, 
control = 1±0.1, anti-GluA2 treated = 0.2±0.05, anti-GluA1 treated = 0.1±0.06; one-way ANOVA, 
followed by Dunn's Multiple Comparison Test, p<0.0001; surface GluA2 band intensity, control = 
0.9±0.1, anti-GluA2 treated = 0.4±0.01, anti-GluA1 treated = 0.5±0.08; one-way ANOVA, p<0.05); 
and no	  significant difference in intracellular GluA1 or GluA2/3 protein (one-way ANOVA, followed 
by Dunn's Multiple Comparison Test, p>0.1). 
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Figure 2: Patient anti-GluA1 or anti-GluA2 antibodies do not alter other synaptic proteins. 
(A) Hippocampal neurons immunostained for the presynaptic marker vGlut or the postsynaptic 
markers PSD-95, GluN1 or Stargazin. Anti-GluA2 patient CSF treatment for 24 hours does not 
reduce vGlut, PSD-95, GluN1 and Stargazin cluster density (n=12-36 neurons from 2-3 
independent experiments). Scale bar = 10 µm. 
(B) Western blot analyses of surface biotinylated NMDAR, GABAB1R, and Stargazin protein (n=3-
6 experiments). 
(C) Quantification excitatory synapse density defined as the colocalization between postsynaptic 
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PSD-95 and presynaptic vGlut density per 20 µm dendrite length from neurons treated with 
control or patient CSF (control = 16±1, patient = 13±2; Mann-Whitney U test, p=0.1). 
(D) Quantification of PSD-95 cluster density (control = 17±1, patient = 15±1; Mann-Whitney U 
test, p=0.16), vGlut cluster density (control = 10±1, patient = 9±1; Mann-Whitney U test, p=0.16), 
GluN1 cluster density (control = 17±1, patient = 16±1; Mann-Whitney U test, p=0.57), 
Stargazin cluster density (control = 18±1, patient = 20±1.8; Mann-Whitney U test, p=0.33) per 20 
µm dendrite length from neurons treated with control or patient CSF. 
(E) Quantification of surface NMDAR, GABAB1R, and Stargazin protein after treatment with serum 
from anti-GluA1 or anti-GluA2 patients, showing no significant changes in these surface proteins 
(one-way ANOVA, p>0.1 for all tests).	  	  
(F) Quantification of the density of dissociated hippocampal cells in vitro after 1 day treatment 
with control or patient CSF (untreated = 21±2, control treated = 20±2, patient treated = 20±2, 
neurons per 750 µm2, n=12 fields from 2 independent experiments; Kruskal-Wallis test, p=0.9). 
(G) Quantification of the percent of TUNEL positive neurons in vitro (apoptotic cells). These 
measures were not significantly different among untreated, control or patient CSF treatment 
(untreated =0.0049±0.0049, control treated = 0.0135±0.0094, patient treated = 0.0052± 0.0052, 
neurons per 750 µm2, n=12 fields (750 µm2), 2 independent experiments; Kruskal-Wallis test, 
p=0.7). 
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Figure 3: Patient antibodies increase the internalization of AMPAR clusters.	  	  
Hippocampal neurons labeled live for surface AMPARs using commercial anti-GluA1 (com-
GluA1) for 1 hour, then treated with control or patient CSF for 1, 4 or 24 hours, 
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followed by immunostaining for the remaining surface com-GluA1 in live neurons. In experiments 
examining internalized com-GluA1, before fixation, neurons were pre-treated with an excess of 
unconjugated secondary antibodies, then fixed, permeabilized and immunostained for internal 
com-GluA1 (n=23 neurons from 3 separate experiments). 
(A) Top and middle panels: Representative dendrites from neurons treated with control or patient 
CSF respectively for 1, 4 or 24 hours and stained for surface com-GluA1. Patient CSF treatment 
caused a greater decrease in surface GluA1 over a 24 hour time period than control. Bottom 
image: dendrites pre-blocked with excessive non-fluorescent secondary antibodies and then 
stained with fluorescent secondary antibody against com-GluA1, showing complete elimination of 
surface staining signal. Scale bar = 10 µm.	  	  
(B) Representative dendrites from neurons treated with control (top) or patient CSF (bottom) for 
1, 4 or 24 hours and stained for intracellular com-GluA1. Patient CSF treatment increased 
intracellular com-GluA1 at 1 and 4 hours compared to controls. Scale bar = 10 µm. 
(C) Quantification of surface com-GluA1 clusters from neurons treated with patient CSF for 1 
hour compared with control neurons (per 20 µm dendrite length, control treated 1 hour = 20±1, 4 
hours = 20±1, 24 hours = 12±1; patient CSF treated 1 hour = 20±1, 4 hour = 14±2, 24 hour = 2±1; 
Mann-Whitney test, 1 hour p=0.3, 4 hour p=0.04, 24 hour p=0.002). The asterisk indicates 
significant difference. 
(D) Quantification of the density of intracellular com-GluA1 clusters from neurons treated with 
control or patient CSF. The asterisk indicates significant difference (control treated 1 hour = 7±1,  
4 hours = 5±0.4; 24 hours = 3±0.3; patient CSF treated 1 hour = 11±1, 4 hour = 14±2, 24 hour = 
4±0.2; Mann-Whitney test, 1 hour p=0.03, 4 hour p=0.003, 24 hour p=0.007). 
(E) Hippocampal neurons were treated with patient CSF for 4 hours, then surface patient 
antibodies were pre-treated by non-fluorescent secondary, and then stained for intracellular 
patient antibodies (green) and the following cell compartment markers (red): EEA for early 
endosome, Lamp1 for lysosome or TrfR for recycling endosome. The upper panels show 
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representative images of dendrites, the bottom panels show images of cell bodies (n=6-7 neurons 
for each condition). Scale bar = 10 µm.	  	  
(F) Quantification of the percentage of internalized patient antibody clusters colocalized with each 
cell organelle marker in dendrites (EEA = 7±1%, Lamp1 = 8±2%, TrfR = 13±2%). 
(G) Quantification of percentage of internalized patient antibody clusters colocalized with each 
cell organelle marker in cell bodies (EEA = 5±1%, Lamp1 = 42±5%, TrfR = 9±3%).	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Figure 4: Commercial antibodies do not have the same effects as patient antibodies. 
(A) Neurons were treated with PBS, commercial anti-GluA2 or anti-GluA1 antibodies directed 
against extracellular epitopes, with and without secondary antibodies to crosslink the primary 
antibodies, or secondary antibodies alone for 24 hours. Neurons were immunostained with an 
anti-GluA1 antibody against an intracellular epitope (if treated with anti-GluA2 antibody) or directly 
with fluorescent secondary (if treated with anti-GluA1) and for the presynaptic marker synapsin. 
Commercial anti-GluA2 antibodies plus secondary antibody treatment for 24 hours decrease 
synaptic GluA1 cluster density (the colocalized yellow puncta are green labeled GluA1 clusters 
colocalized with red synapsin clusters, indicating synaptic GluA1; n=6-13 neurons from three 
experiments.) Scale bar = 10 µm.  
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(B) Quantification of the percentage of synaptic AMPAR cluster density per 20 µm dendrite length 
from neurons treated with commercial GluA1 antibody or commercial GluA2 antibody compared 
to neurons treated with PBS (compare to PBS control, GluA1 1:20 = 225±11%, GluA1 1:50 = 
238±26%, GluA1 1:100 = 112±12%, GluA1 1:500 = 138±15%, GluA2 1:100 = 78±5%, GluA2 
1:500 = 80±6%, GluA2 1:100 plus secondary = 61±5%, GluA2 1:500 plus secondary 1:500 = 
44±3%, secondary only 1:500 = 91±13%. One-way ANOVA followed by Dunn’s multiple 
comparison test, p<0.0001, asterisk indicates significant decrease, pound indicates significant 
increase).	  	  
(C) Quantification of internalization of GluA1 clusters pre-labeled with a commercial antibody per 
20 µm dendrite from neurons also treated with a commercial GluA1 antibody, a commercial 
GluA2 antibody or patient antibodies (n=11-13 neurons from 3 experiments, 0 hours = 1±0.3, 
GluA1 1:100= 2±0.4, GluA1 1:50 = 2±0.5, GluA2 1:500 4 hours = 4±0.4, GluA2 plus secondary 
1:500 = 9±0.8, patient CSF = 17±1; Kruskal-Wallis test, p<0.0001, asterisk indicates significant 
difference). 
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Figure 5: Patient antibodies decrease AMPAR- but not NMDAR-mediated synaptic 
transmission.	   
(A) mEPSCs recorded in physiological saline with TTX, picrotoxin, and APV to isolate synaptic 
AMPAR-mediated currents (upper trace; n=9 neurons treated with control CSF, 4-7 neurons 
treated with patient CSF for 1, 4 or 24 hours). Left: Under the same recording conditions, 
treatment of hippocampal neurons with patient CSF (bottom traces) for 1 day dramatically 
reduces synaptic AMPAR-mediated currents. Right: Representative average mEPSCs from 
neurons treated for 1 day with control CSF (left) or patient CSF (right). Neurons treated with 
patient CSF have smaller AMPAR-mediated synaptic current than neurons treated with control 
CSF. 
(B) mEPSCs recorded in physiological saline with TTX, picrotoxin and CNQX, to isolate synaptic 
NMDAR-mediated currents. Left: Neurons treated with control (upper trace) and patient CSF 
(bottom traces) for 1 day have comparable synaptic NMDAR-mediated currents. Right: 
Representative average mEPSCs from neurons treated for 1 day with control CSF (left) or patient 
CSF (right), showing comparable synaptic NMDAR-mediated currents (n=10 neurons treated with 
control CSF, 9 neurons treated with patient CSF. 
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(C) Effect of patient antibodies on AMPAR-mediated synaptic current amplitude (in pA, control = 
15±1, patient CSF treated 1 hour = 12±2, patient CSF treated 4 hours = 10±1, patient CSF 
treated 24 hours = 10±1; asterisk indicates significant difference, one-way ANOVA, p=0.01).	  	  
(D) Effect of patient antibodies on AMPAR-mediated synaptic current frequency (in Hz, control = 
8±1, patient CSF treated 1 hour = 5±2, patient CSF treated 4 hours = 2±0.4, patient CSF treated 
24 hours = 2±0.8; asterisk indicates significant difference, one-way ANOVA, p=0.0017). 
(E) Effect of patient antibodies on NMDAR-mediated synaptic current amplitudes (in pA, control = 
16±1, patient CSF treated = 18±2; Student’s t-test, p=0.2).	  	  
(F) Effect of patient antibodies on NMDAR-mediated synaptic current frequency (in Hz, control = 
0.7±0.1, patient CSF treated = 1±0.3; Student’s t-test, p=0.44). 
(G) Effect of patient antibodies on NMDAR-mediated synaptic currents decay time (in ms, control 
= 66±9, patient CSF treated = 88±8; Student’s t-test, p=0.09).	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Figure 6: Homeostatic decrease of GABAAR-mediated synaptic transmission. 
(A) mIPSCs were recorded in physiological saline with TTX, CNQX and APV to isolate synaptic 
GABAAR-mediated currents. Hippocampal neurons treated with patient CSF (bottom left trace) for 
1 day have fewer mIPSCs compared to control (upper left trace). The average amplitude of 
GABAAR-mediated mIPSCs in neurons treated with patient CSF (bottom right trace) was similar 
from control (bottom left trace; n=8 control CSF treated neurons, 6 patient CSF treated neurons). 
(B) Effect of patient antibodies on GABAAR-mediated mIPSC frequency (in Hz, control = 1.6±0.5, 
patient CSF treated = 0.4±0.2; asterisk indicates significant difference, Student’s t-test, p=0.03). 
(C) Effect of patient antibodies on GABAAR-mediated mIPSC amplitudes (in pA, control = 37±2, 
patient CSF treated = 35±3; Student’s t-test, p=0.7). 
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(D) Hippocampal neurons immunostained for the inhibitory presynaptic marker vGAT (red) and 
the postsynaptic marker GABAAR (green). Inhibitory synapses are defined as the colocalization 
between vGAT and GABAAR staining. Patient CSF or CNQX treatment for 24 hours reduces 
vGAT staining intensity, while patient CSF plus KCl (25 mM) increases vGAT intensity, compared 
to neurons treated with control CSF (n=15-24 neurons from 3 independent experiments). Scale 
bar = 10 µm. 
(E) Quantification of inhibitory synapse density. Numbers of immunofluorescence labeled puncta 
per 20 µm dendrite were normalized to controls for each trial. Neurons were treated with control 
CSF,	  patient CSF, CNQX, patient CSF plus KCl (25 mM) or KCl (25 mM). The density of 
inhibitory synapses was comparable among conditions (Mann-Whitney U test, p=0.5). 
(F) Cumulative distribution of vGAT intensity on neurons treated with control CSF (black solid 
line), patient CSF (red solid line), CNQX (green solid line), patient CSF plus KCl (red dotted line) 
or KCl (black dotted line). Patient CSF or CNQX treated neurons have decreased vGAT staining 
intensity compare to the control (Kolmogorov–Smirnov test, p<0.0001), while KCl alone or KCl 
plus patient CSF treated neurons have increased vGAT staining (Kolmogorov–Smirnov test, 
p<0.0001).	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Figure 7: Homeostatic increase of neuronal excitability and patient antibody effects on 
spontaneous firing. 
(A) Representative traces of action potential firing during current injection (upper traces, 0 pA, 40 
pA, 100 pA, 200 pA) in control treated neurons (middle traces), and patient CSF treated neurons 
(bottom traces). The recording was done in the presence of APV, CNQX and PTX to block 
synaptic transmission (n=7 control neurons, 6 patient CSF treated neurons). 
(B) Quantification of action potential firing versus current injection, showing significant increase 
of neuronal excitability in patient CSF treated neurons (Mann-Whitney U test, p<0.05 for 0, 40, 
60, 80,100, 120, 140, 180 and 200 pA). 
(C) Average input resistance was higher in patient CSF treated neurons than in controls (in MΩ, 
control = 294±29, patient CSF treated = 448±51; asterisk indicates significant difference, 
Student’s t-test, p=0.04). 
(D) Representative traces of spontaneous action potential firing in control (upper trace) or patient 
CSF treated neurons (bottom trace) without synaptic transmission blockers. The boxed segments 
are	  shown at slower time scale on the right (n=5 control neurons, 6 patient CSF treated neurons). 
(E) Average action potential firing frequency was not significantly different in control or patient 
CSF treated neurons (in Hz, control = 1.6±0.3, patient CSF treated = 1.7±0.5, Student’s t-test, 
p=0.9). 
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(F) Cumulative distribution of action potential inter-spike intervals of neurons treated with control 
CSF (dotted line) or patient CSF (solid line). Asterisk indicates that these two distributions are 
significantly different (Kolmogorov–Smirnov test, p<0.0001). 
(G) Comparison of percentage of short interval spikes (with <10 ms intervals) in control treated or 
patient CSF treated neurons (in %, control treated = 1.3±0.7, patient treated = 11±5; asterisk 
indicates significant difference, Student’s t-test, p=0.02). 
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Table 1: Patient samples used in each experiment and specific antibodies in each sample 
Figure Number Experiment/treatment Patient CSF ID (Specific 
antibodies 
1A Hippocampal neuron 
immunostaining with patient CSF 
04-067 (GluA1), 02-066 
(GluA2) 
1B-E Treatment with patient CSF and 
immunostaining of synaptic 
AMPAR clusters 
09-276 (GluA1), 04-067 
(GluA1), 02-066 (GluA2) 
1F-H, 2B,E Treatment with patient serum and 
Western analysis 
04-067 serum (GluA1), 02-
066 serum (GluA2) 
2A, C, D Treatment with patient CSF and 
immunostaining of other synaptic 
markers 
04-067 (GluA1), 02-066 
(GluA2) 
2F, G Treatment with patient CSF and 
cell death analysis 
02-066 (GluA2) 
3 Treatment with patient CSF and 
internalization assay 
02-066 (GluA2) 
5 Treatment with patient CSF and 
recording of AMPAR and 
NMDAR-mediated miniature 
currents 
04-067 (GluA1), 02-066 
(GluA2) 
6 Treatment with patient CSF and 
GABAAR-mediated currents 
02-066 (GluA2) 
7A-D Treatment with patient CSF and 
cell excitability 
02-066 (GluA2) 
7E-G Treatment with patient CSF and 
cell spontaneous firing 
04-067 (GluA1) 
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Abstract  
 Objective: Antibodies from patients with anti-NMDAR encephalitis cause homeostatic 
plasticity of inhibitory synapse density. In this study, we sought to determine if intrinsic excitability 
was also altered, and possible mechanisms underlying the expression of this plasticity. In 
addition, we establish and validate organotypic hippocampal slice cultures as a new model 
system for cellular and circuit studies of autoimmune encephalitides. 
 Methods: Current-clamp recordings from dissociated hippocampal neurons were made to 
measure antibody-induced changes in intrinsic excitability. Organotypic hippocampal slice 
cultures were used to assay effects of patient antibodies on NMDAR clusters and currents, and 
interneuron integrity.  
 Results: Patient antibody treatment increased neuronal excitability in dissociated 
hippocampal neurons. Input resistance and threshold to firing remained unchanged, while the 
resting membrane potential became depolarized. Action potential height, width, and 
accommodation were unchanged, as were voltage-gated potassium currents. Treatment of 
organotypic hippocampal slices with patient antibodies caused a decrease in NMDAR-mediated 
field potentials, as well as NMDAR staining, protein levels and parvalbumin immunoreactivity, 
without changes in the pan-interneuron marker GAD65/67.   
 Interpretation: These results demonstrate that anti-NMDAR antibodies can induce 
homeostatic plasticity of intrinsic excitability, and that different membrane properties may underlie 
this phenomenon following anti-NMDAR and anti-AMPAR antibody treatment. Hippocampal slice 
cultures can be used as a more intact system to investigate synaptic and circuit effects of 
antibody treatment, and resultant homeostatic changes in these circuits. 
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Introduction 
 Homeostatic plasticity is an important and widespread mechanisms for stabilizing 
neuronal activity in the face of fluctuations due to development, disease, or Hebbian synaptic 
plasticity.1 In contrast to other forms of plasticity, such as long-term potentiation and depression, 
which operate on a time scale of minutes to hours, homeostatic plasticity is thought to emerge 
over longer time frames, from many hours to days. Pharmacological manipulations that increase 
or decrease activity levels can trigger distinct forms of homeostatic plasticity, expressed at the 
synapse or through intrinsic membrane properties.2 Alone or in combination, these modifications 
tend to allow neurons to maintain a set-point level of activity.    
 Paradoxically, seizures are a major symptom of both anti-NMDAR and anti-AMPAR 
encephalitis.3,4 The seemingly contradictory nature of two diseases marked by a loss of excitatory 
glutamate receptors leading to the development of epileptic seizures can be reconciled within the 
context of homeostatic plasticity. Although commonly thought of as an adaptive or stabilizing 
force, there are instances of homeostatic plasticity inadvertently creating an imbalance in 
excitation versus inhibition,5-7 that could become pathological.  
Previous work has shown that neurons treated with patient anti-AMPAR antibodies 
compensate for reduced excitatory drive through glutamatergic synapses by adjusting inhibitory 
synapse strength and intrinsic excitability, but at the expense of firing pattern fidelity.8 Similarly, 
anti-NMDAR antibodies cause a homeostatic decrease in inhibitory synapse density onto 
excitatory neurons,9 but their effect on neuronal excitability is unknown. Other models of NMDAR 
hypofunction have reported plasticity of intrinsic excitability,10 raising the possibility that patient 
antibodies generate a similar response. A second possible mechanism that could underlie seizure 
development in anti-NMDAR encephalitis is dysfunction in a subset of inhibitory neurons, the fast-
spiking parvalbumin-positive (PV+) interneurons, an occurrence known to take place in several 
pharmacological and genetic models of NMDAR hypofunction.10-14  
Here we investigated these two possible causes of altered excitatory-inhibitory balance in 
response to anti-NMDAR antibodies. We report that patient antibodies increase cultured 
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hippocampal neuron excitability, possibly through a depolarization of the resting membrane 
potential. In addition, we established an organotypic hippocampal slice culture system and 
verified that patient antibody treatment decreased NMDAR protein levels and NMDAR-mediated 
field potentials. Finally, we used the hippocampal slices to assay changes in parvalbumin 
immunoreactivity and found that patient antibodies cause a decrease the intensity of parvalbumin 
staining but not in the number of parvalbumin-positive cells, without changes in the pan-
interneuron marker GAD65/67. Together, these data further our understanding of homeostatic 
mechanisms in this disease, and set the stage for future studies in in vivo models.      
   
 
 
113	  
Materials and Methods 
Cell culture and treatment 
Hippocampal neurons were prepared and maintained from embryonic day 18 rat pups as 
previously described.15 Neurons were treated on in vitro day 14-16 (DIV14-16) with cerebrospinal 
fluid (CSF) from patients or controls at a dilution of 1:20.  
 
Organotypic slice culture and treatment 
Hippocampal slice cultures were prepared from rat pups P5-7 as previously described.16 Briefly, 
pups were anesthetized and hippocampi dissected in ice-cold, oxygenated ACSF containing the 
following in mM: 85 NaCl, 2.5 KCl, 1.25 NaH2PO4, 75 sucrose, 25 glucose, 0.5 ascorbic acid, 4 
MgSO4, 25 NaHCO3, 0.5 CaCl2. 300 µm-thick sections were cut on a McIlwain tissue chopper 
and plated onto Millipore cell culture inserts in slice culture media (8.4 g/L MEM Eagle medium, 
20% horse serum, 1 L-glutamine, 1 CaCl2, 2 MgSO4, 1 mg/L insulin, 0.00125% ascorbic acid, 13 
glucose, 5.2 NaHCO3, 30 HEPES). Slices were maintained in a humidified incubator at 37°C with 
5% CO2.  
 
Immunostaining 
Slice cultures were treated for 72 hours and incubated with the following primary antibodies: to 
label NMDARs, anti-GluN1 (Millipore; AB9864R, 1:100); inhibitory neurons, anti–glutamic acid 
decarboxylase 6 (GAD6; Developmental Studies Hybridoma Bank, Iowa City, IA; 1:20); 
parvalbumin-positive neurons, anti-parvalbumin (Sigma; P3088, 1:100). The secondary 
antibodies (Invitrogen) were raised in goat against rabbit, mouse, or human immunoglobulin G 
(IgG) and conjugated to various Alexa Fluor dyes. Slices were mounted and imaged on a 
confocal microscope (Leica, Wetzlar, Germany; TCS SP5) and analyzed using interactive 
software (custom-written ImageJ macros).15  
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Western blot 
Slice cultures were washed with PBS and lysed in RIPA buffer (150mM NaCl, 1mM EDTA, 
100mM Tris-HCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pH=7.4), supplemented 
with 1:500 protease inhibitor mixture III (Calbiochem) at 4°C for 1 h. Lysates were sheared by 
passage through a 22-gauge syringe and cleared of debris by centrifugation at 12,4000g for 20 
minutes. Protein samples were separated on 4-15% SDS-PAGE gel and transferred to 
nitrocellulose membranes. Blots were probed with antibodies against GluN1 (Millipore, 1:1000) 
and MAP2 (Abcam, 1:1000).  
 
Electrophysiology 
Whole-cell current-clamp recordings were performed at room temperature using a Multiclamp 
700B amplifier and pClamp 10 data acquisition software. Neurons were incubated in extracellular 
physiology solution (in mM): 140 NaCl, 3 KCl, 0.6 MgCl2, 2.5 CaCl2, 10 HEPES, 10 glucose. 
Picrotoxin (10 µM), APV (50 µM) and CNQX (10 µM) were added to block synaptic currents. 
Borosilicate glass microelectrodes (resistance 4-6 M) filled with intracellular solution (in mM): 140 
KCl, 2 MgCl2, 11 EGTA, 10 HEPES, 7 glucose, pH=7.3. Traces were amplified, sampled at 20 
kHz, then digitally low-pass filtered at 2.5 kHz and events were analyzed using Clampfit.   
For field potential recordings, slice cultures were placed in a recording chamber and perfused 
with warmed (30°C), oxygenated ACSF containing (in mM): 126 NaCl, 2.5 KCl, 1.25 Na2HPO4, 10 
glucose, 26 NaHCO3, 2.5 CaCl2. Picrotoxin (10 µM) and CNQX (10 µM) were added to isolate 
NMDAR-mediated potentials. A bipolar stimulating electrode was placed near the border of CA3-
CA1 in the Schaffer collaterals, and an ACSF-filled recording electrode (resistance 1-2MΩ) was 
placed in the stratum radiatum in CA1. Evoked field potentials were amplified, sampled at 20 kHz, 
then digitally low-pass filtered at 2.5 kHz and slopes were analyzed using Clampfit.     
 
Statistical analysis 
Data sets were analyzed using a Mann-Whitney U test or 2-way analysis of variance test. 
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Results 
Patient anti-NMDAR antibodies cause a homeostatic increase in intrinsic excitability 
 Patient antibodies abrogate NMDAR-mediated miniature excitatory postsynaptic currents 
in hippocampal neurons in vitro,15 and cause a resultant compensatory decrease in inhibitory 
synapse density onto pyramidal neurons.9 To assess whether another common locus of 
homeostatic plasticity, intrinsic excitability, was altered in response to patient cerebrospinal fluid 
(CSF) treatment, hippocampal neuron cultures (DIV15-18) were treated for 24-48 hours. Whole-
cell current clamp recordings were used to measure action potential firing frequency in response 
to depolarizing current injection in the presence of synaptic blockers.  
 Hippocampal neurons rarely fire spontaneously under such conditions, but current 
injection will elicit one or more action potentials (Fig 1A). Patient CSF treatment increases the 
number of action potentials fired in response to injection of a given amount of current, and also 
causes neurons to fire more spontaneous action potentials even in the absence of stimulation 
(Fig 1A, B).  
This phenomenon also occurs following treatment with anti-AMPAR antibodies.8  
Interestingly, our data suggests that different mechanisms may underlie the increased excitability 
in these two cases. Treatment with anti-NMDAR encephalitis patient CSF significantly 
depolarizes the resting membrane potential (Fig 1C) with no change in either threshold to firing or 
input resistance (Fig 1D). In contrast, hippocampal neurons treated with CSF from patients with 
anti-AMPAR encephalitis have no change in resting membrane potential or threshold to action 
potential firing, but input resistance is increased (8 and Figure 1D).  
These results suggest that exposure to anti-NMDAR and anti-AMPAR antibodies leads to 
an increase in intrinsic neuronal excitability, but that these different scenarios may engage 
separate mechanisms to achieve this compensation. 
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Patient antibody treatment does not change spike frequency adaptation or action potential shape  
 To gain further insight into the ionic mechanisms underlying the increased excitability of 
hippocampal neurons treated with anti-NMDAR antibodies, we analyzed certain well-defined 
parameters of action potential firing. The first was spike frequency adaptation (SFA), the 
reduction of firing frequency over time during current injection,17 a process that can be influenced 
by multiple ionic currents.18,19  The ability of neurons to fire more action potentials in response to a 
given amount of current could be due to attenuated SFA during the current step. SFA was 
measured as the ratio of initial firing frequency to final firing frequency.18 Both control and patient 
treated neurons showed this adaptation (SFA>1), and the magnitude as a function of current 
injection was not different between conditions (Fig 1E).  
 Next, we measured action potential width, height, and peak voltage, characteristics that 
can also be modulated by multiple conductances. None were altered by patient antibody 
treatment (Fig 1F-H). Last, we measured voltage-gated potassium currents, a large family known 
to have varied effects on firing frequency and excitability. Neither current amplitude nor voltage-
dependence of activation was altered (Fig I, J).  
 
Patient antibodies decrease NMDAR clusters and currents in organotypic hippocampal slice 
cultures 
 The use of dissociated hippocampal neuron cultures facilitated a detailed mechanistic 
description of antibody-mediated NMDAR and AMPAR hypofunction and the homeostatic 
response of hippocampal neurons to the loss of glutamatergic synaptic transmission. To begin to 
narrow the gap between a model of cultured neurons and disease, an organotypic hippocampal 
slice culture system was established. Organotypic hippocampal slices are an ideal preparation for 
our studies, because they largely retain the synaptic circuitry and developmental trajectory found 
in vivo, are amenable to physiological and histological assays, and can be maintained for up to 
three weeks in culture,20 allowing for multi-day treatment with patient antibodies. Slices were 
 
 
117	  
prepared from P5-7 rat pups, and used for immunohistochemistry, Western blotting and 
physiology between DIV7-14.  
 Following treatment with patient CSF, slices were stained with deposits of human 
immunoglobulin (IgG) and the intensity of NMDAR immunoreactivity was significantly decreased 
(Fig 2A,C). This result was verified with Western blotting (Fig 2B), and mirrors results in 
dissociated hippocampal neurons.  
 Extracellular recordings were made to measure the effects of patient CSF on evoked 
NMDAR currents. We focused on the Schaffer collateral pathway, where axon collaterals from 
CA3 pyramidal neurons synapse onto the dendrites of CA1 pyramidal neurons and in which 
dynamics of glutamatergic transmission have been well described. Schaffer collateral axons were 
stimulated in CA3 and the resultant field excitatory postsynaptic potentials (fEPSP) were 
measured in the stratum radiatum of CA1. CNQX (10 µM) and picrotoxin (10 µM) were added to 
isolate the NMDAR component of the fEPSP. Patient CSF caused a decrease in the slope of the 
NMDAR-mediated fEPSPs (Fig 2D), indicating a loss of postsynaptic NMDAR-mediated currents.  
 These data together show that, as in dissociated hippocampal neurons, patient antibody 
treatment causes a loss of NMDAR clusters and currents in hippocampal slices.  
 
Patient antibodies alter parvalbumin immunoreactivity 
 In hippocampal neuron cultures, NMDAR hypofunction due to treatment with patient CSF 
results in a homeostatic decrease in inhibitory synapse density onto excitatory pyramidal 
neurons.9 In several genetic and pharmacological models of NMDAR hypofunction, there are 
abnormalities specifically in PV+ interneurons, including a decrease in mRNA and protein 
expression of the calcium binding protein for which the cell type is named, parvalbumin.10-14 As 
these neurons target perisomatic regions and axon initial segments of pyramidal neurons, they 
exert a powerful influence on neuronal firing and synchrony, and therefore information processing 
in the brain.21-23 To test if anti-NMDAR antibodies elicited similar alterations in parvalbumin 
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expression, hippocampal slice cultures were treated with patient CSF and processed for 
immunohistochemistry.  
 The number of PV+ interneurons was unchanged following treatment (Fig 2E); however, 
the intensity of immunoreactivity per neuron was decreased (Fig 2F). There were no changes in 
expression of GAD65/67 (Fig 2E, F). This is consistent with studies from other models,14 and 
suggests that like pharmacological models of NMDAR hypofunction, PV+ interneuron dysfunction 
may be a pathologic mechanism in anti-NMDAR encephalitis.  
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Discussion 
We have described two effects of anti-AMPAR and anti-NMDAR antibody treatment that 
could plausibly lead to the development of seizures in patients. The first is homeostatic plasticity 
of intrinsic excitability, which augments action potential firing, and in the case of anti-AMPAR 
encephalitis, changes the firing pattern. The second is a loss of parvalbumin immunoreactivity, in 
response to anti-NMDAR antibodies, in a subset of hippocampal interneurons, indicative of 
inhibitory neuron dysfunction. These changes, while probably engaged as neurons attempt to 
compensate for the antibody-induced partial loss of excitatory synaptic transmission, may instead 
lead to hyperexcitability and contribute to patient symptoms and disease progression.    
 
Mechanisms of homeostatic plasticity 
 Action potential firing is the major output mode for neurons. As such, it is a variable and 
tightly regulated code. Apart from diverse spatial and temporal combinations of synaptic input, 
action potential firing can be shaped by the vast repertoire of ion channels embedded in the 
neuronal membrane.24 Homeostatic plasticity of intrinsic excitability could engage any number of 
these conductances. In cortical neurons, activity blockade leads to an increase in excitability that 
is mediated by a decrease in threshold to firing, an increase in voltage-gated sodium 
conductance and a decrease in persistent outward potassium currents.25 These changes may be 
downstream of BDNF.26 In guinea pigs and rats, unilateral vestibular lesions produce a 
compensatory increase in firing in neurons on the injured side through the concerted actions of 
several conductances.27,28 In invertebrate systems, isolation of neurons in culture initially 
abrogates firing, but normal activity patterns recover within a few days, as a result of modulation 
of several intrinsic conductances, including sodium, potassium, and calcium currents.29 
In the case of anti-NMDAR antibodies, the resting potential is depolarized compared with 
control treatment. This could arise from changes in several potassium conductances, including 
inward rectifiers (KIR),30,31 2 pore domain K+ channels (K2P),32 or M-currents (KCNQs).33 In 
contrast, anti-AMPAR antibodies increase the input resistance of the neuronal membrane, 
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indicating a decreased density of one or more types of channels normally open at hyperpolarized 
resting potentials.34  
The enhanced excitability of neurons following anti-NMDAR antibody exposure is 
consistent with other models of NMDAR hypofunction. Ketamine, an NMDAR blocker, activates 
the prefrontal cortex in humans and rats.35,36 MK-801, a use-dependent NMDAR antagonist, 
decreases the firing rate of interneurons and increases the rate of pyramidal neuron firing in the 
hippocampus.37 Chronic MK-801 decreases inhibitory post-synaptic potential (IPSP) amplitude in 
CA1 hippocampal neurons.14 Interestingly, infusion of CSF from anti-NMDAR encephalitis 
patients raises concentrations of extracellular glutamate in hippocampus and cortex.38 While 
these findings are usually attributed to synaptic effects (i.e., loss of NMDAR function on inhibitory 
interneurons causing disinhibition of excitatory neurons), our findings raise the possibility that 
changes in intrinsic excitability may play an additional role.   
The observed increase in excitability may help explain not only patient seizures, but also 
other cognitive deficits. There is a high link between seizures and many neuropsychiatric 
conditions.39-41 Disturbances in the excitatory-inhibitory balance have been connected with both 
autism and schizophrenia, and increasing the ratio of excitation to inhibition leads to behavioral 
impairments in rodent models, including diminished social interactions and impaired fear 
learning.10,42-45 The input-output curves of individual neurons are more easily saturated, which 
could cause problems with information processing and learning and memory.42 These data 
support the idea that altered excitatory-inhibitory balance in anti-glutamate receptor 
encephalitides may be at the root of many seemingly diverse symptoms.     
 
Parvalbumin-positive interneuron dysfunction 
 Another common finding among disparate models of impaired NMDAR hypofunction is 
abnormal gene and protein expression in PV+ interneurons.10-14 Axon terminals of this class of 
fast-spiking inhibitory neuron target the axon initial segment and perisomatic regions of excitatory 
neurons, exerting a powerful influence on pyramidal neuron firing and synchrony.21-23 PV+ 
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neurons are instrumental for rhythmogenesis, especially for synchronizing gamma-frequency 
oscillations, which have a crucial role in facilitating working memory and perceptual binding. In 
fact, behavioral deficits in a model of excitation-inhibition imbalance can be rescued by exciting 
PV+ interneurons.42 The power of gamma-frequency oscillations is often disrupted in 
schizophrenia, in human patients and animal models.46 Consistently, the proper functioning of 
PV+ interneurons has become a fruitful source of inquiry in the field of schizophrenia research.  
Post-mortem studies of schizophrenia patients have revealed several consistent 
findings.47 Gamma-aminobutyric-acid (GABA) expression is reduced in PV+ interneurons, as is 
expression of GAD65/67, a GABA synthesizing enzyme. The mRNA and protein levels of 
parvalbumin are also diminished. One explanation for this finding again invokes homeostatic 
plasticity; as a calcium-binding protein, parvalbumin abrogates the Ca2+-based facilitation of 
GABA release from presynaptic terminals. As inhibitory synapse density and the immunoreactivity 
of vGAT+ terminals falls in response to loss of glutamatergic drive, levels of PV may decrease to 
enhance GABA release.  
Interestingly, NMDARs have a prominent role in proper PV+ interneuron functioning. PV+ 
interneurons have substantial NMDAR-driven synaptic responses,48 and ablation of NMDARs on 
this class of interneurons impairs firing in the gamma and theta frequencies, leading to deficits in 
spatial recognition memory, working memory, and sociability.49,50 Following administration of 
many pharmacological NMDAR blockers, including ketamine and phencyclidine (PCP), and in a 
genetic rodent model of NMDAR hypofunction, parvalbumin expression is diminished.10-14 
Consistently, treatment of organotypic hippocampal slices with anti-NMDAR antibodies decreases 
parvalbumin expression. Together with other data, we have identified at least three potential 
routes by which patient antibodies could perturb excitatory-inhibitory balance, leading to seizures 
and cognitive deficits—reduced density of inhibitory presynaptic terminals, enhanced intrinsic 
excitability, and a loss of parvalbumin expression.   
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Establishment of organotypic hippocampal slice system 
We described the development of a new model for future studies of patient antibody 
effects. Organotypic hippocampal slices have several advantages over dissociated hippocampal 
neurons. First, hippocampal architecture remains intact, allowing for an analysis of the structure 
and function of the circuits therein after antibody treatment. Second, the older age of the animals 
used to generate slices means gene expression of certain interneuron classes has turned on, 
such as parvalbumin. Finally, phenomena such as homeostatic plasticity, which may be 
expressed differently in culture versus an intact slice, can be studied in a more physiologically 
relevant context.16,20 Along with a recently developed animal model of anti-NMDAR encephalitis,51 
hippocampal slice cultures will allow the gap between synaptic mechanisms of dysfunction and 
human disease to begin to narrow. 
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Figure 1: Patients antibodies cause a homeostatic increase in neuronal excitability  
(A) Representative traces of action potential firing during current injection (upper traces, 0 pA, 40 
pA, 100 pA, 200 pA) in control treated neurons (middle traces), and patient CSF treated neurons 
(bottom traces; (n=6 control neurons, 6 patient CSF treated neurons). 
(B) Quantification of action potential firing versus current injection, showing significant increase 
of neuronal excitability in patient CSF treated neurons (Mann-Whitney test, p<0.05 for 170, 270, 
and 290 pA). 
(C) Average input resistance in control (370.7±61.2 MΩ) and patient (321.0±84.06) treated 
neurons was not significantly different (Mann-Whitney test, p>0.05). 
(D) Quantification of average resting membrane potential for control versus NMDAR CSF treated 
(top left, -66.35±2.16 and -58.77±1.77) and control versus AMPAR CSF treated neurons (top 
right, -58.73±3.27 and -52.15±0.93), and average threshold for firing for control versus NMDAR 
CSF treated (bottom left, -31.56±3.86 and -36.44±1.36) and control versus AMPAR CSF treated 
neurons (bottom right, -35.00±1.13 and -34.83±0.90). Only the difference in resting potential for 
NMDAR CSF treated neurons was significantly different (Mann-Whitney test, p<0.05). 
(E) Quantification of spike frequency adaptation (SFA) ratio versus current injection, showing no 
change between control and patient CSF (Mann-Whitney test, p>0.05). 
(F) Quantification of action potential height versus current injection, showing no change between 
control and patient CSF (Mann-Whitney test, p>0.05). 
(G) Quantification of action potential width versus current injection, showing no change between 
control and patient CSF (Mann-Whitney test, p>0.05). 
(H) Quantification of action potential amplitude versus current injection, showing no change 
between control and patient CSF (Mann-Whitney test, p>0.05). 
(I) Current-voltage (I-V) curves for voltage-gated potassium currents; current amplitudes for a 
given holding voltage are unchanged by patient antibody treatment. 
(J) Voltage-dependence of potassium channel activation is unchanged by patient antibody 
treatment.
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Figure 2: Patient antibodies decrease NMDAR clusters and currents and parvalbumin 
immunoreactivity in organotypic hippocampal slice cultures  
(A) Hippocampal slice cultures were immunostained for total GluN1 and human IgG following 
treatment for 72 hours with control or patient CSF and imaged with confocal microscopy. Scale 
bar = 50 µm 
(B) Hippocampal slice cultures were processed for Western blotting following treatment for 72 
hours with control or patient CSF. Blots were probed for GluN1, and MAP2 was used as a loading 
control. Patient CSF treatment causes a decrease in GluN1 protein levels. 
(C) Quantification of GluN1 and human IgG staining intensity. Patient antibody treatment caused 
a significant decrease in GluN1 immunoreactivity (78.50±6.54% of control), and a significant 
increase in human IgG staining (218.8±25.79% of control; n=22-34 slices from 4 independent 
experiments). Asterisk indicates significance; Mann-Whitney test, p<0.05. 
(D) Hippocampal slice cultures were treated for 72 hours with control or patient CSF, then 
extracellular recordings were made from the stratum radiatum of CA1. The slope of the NMDAR-
mediated portion of the field excitatory postsynaptic potential (fEPSP) was significantly decreased 
following patient antibody exposure (control, 0.40±0.06; patient 0.20±0.07; n=4). Asterisk 
indicates significance; Mann-Whitney test, p<0.05. 
(E) Hippocampal slice cultures were immunostained for parvalbumin and a pan-inhibitory marker, 
GAD65/67, following treatment for 72 hours with control or patient CSF and imaged with confocal 
microscopy. Scale bar = 50 µm 
(F) Quantification of parvalbumin (PV) and GAD65/67 staining intensity. Patient antibody 
treatment caused a significant decrease in somatic parvalbumin staining intensity, but no change 
in somatic GAD65/67 intensity (parvalbumin, 89.58±2.23% of control, n=7; GAD65/67, 
111.1±4.55% of control; n=2). Asterisk indicates significance; Mann-Whitney test, p<0.05. 
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CHAPTER 5. CONCLUSIONS & FUTURE WORK 
  
The studies discussed in previous chapters have advanced our understanding of a novel 
class of autoimmune encephalitides. My work using in vitro cell culture and slice models of anti-
NMDAR and anti-AMPAR encephalitis uncovered previously unknown pathogenic mechanisms 
and homeostatic effects of patient antibody exposure. Data showed that patient antibody binding 
to NMDAR or AMPAR caused a decrease in synaptic transmission through that receptor via 
internalization (Fig 1, schematic for anti-NMDAR encephalitis). This glutamatergic hypofunction 
led to compensatory changes in inhibitory synapse strength and intrinsic excitability, which 
altered spontaneous action potential firing in response to remaining synaptic input.  
To facilitate an in vivo examination of the circuit dysfunction and behavioral impairments 
of these disorders, an animal model of anti-NMDAR encephalitis has recently been developed 
and validated.1 Mice are infused intraventricularly with patient antibodies for 14 days, and 
continue to be monitored up through 46 days. Antibody deposition and NMDAR down-regulation 
peak at 18 days, then subsequently recover. Patient antibody-infused mice have memory 
impairments, anhedonia, and depression, without changes in anxiety, aggression, or locomotor 
activity. Thus, the animal model exhibits many features, both histological and behavioral, of 
human patients.  
This exciting in vivo work opens the door for a myriad of studies. Homeostatic changes in 
response to patient antibody treatment can be monitored in vivo, in distinct circuits and cell types 
(interneurons, pyramidal neurons). Further dissection of the mechanisms of plasticity can be 
undertaken, as well. For example, what specific ion channels underlie the increased excitability in 
response to anti-NMDAR and anti-AMPAR antibodies? What conductances facilitate the 
transition to a more ‘bursting’ phenotype in response to anti-AMPAR antibody treatment, and 
does a similar change occur after anti-NMDAR antibody treatment?  
Several conductances are known to contribute to burst firing, including those underlying 
after-hyperpolarizations (IKCa2+, a calcium-dependent potassium current) and depolarizing after-
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potentials (INaP, persistent sodium current; IT, low-threshold activated calcium current).2-5 
Additionally, synaptic mechanisms can regulate burst firing. Inhibition by GABAARs and 
GABABRs decreases, and blockade of GABAARs by bicuculline enhances, the tendency to fire in 
bursts.6-8 Apart from mechanisms, the functional and behavioral implications of this change in 
action potential firing are best addressed in an animal model. Burst firing has been proposed to 
improve the signal-to-noise ratio and to increase the reliability of presynaptic vesicle release.9 
This may result in inappropriate gating and over-responsiveness to stimuli, as well as triggering 
seizures.   
NMDARs and AMPARs are involved in Hebbian as well as homeostatic plasticity.10 
Defects in spike-timing dependent plasticity and long-term potentiation and depression in 
response to antibody infusion could be assayed in slices taken from treated animals with memory 
impairments. It would be interesting to know if, in addition to the anti-glutamate receptor 
encephalitides, other autoimmune diseases of synapses, such as those targeting GABABRs, 
GABAARs, LGI, and CASPR2, induce homeostatic plasticity. Finally, the ‘sensor’ that the neurons 
use to monitor their activity is unknown. In many systems intracellular calcium is thought to be the 
read-out,11-13 which could explain how and why NMDAR and AMPAR hypofunction trigger these 
modifications.   
The parallels between schizophrenia and anti-NMDAR encephalitis are fascinating and 
largely unexplored. Both diseases share symptoms of psychosis and cognitive deficits, and 
NMDAR hypofunction is likely to contribute to schizophrenia. Several genes linked to 
schizophrenia impact NMDAR function, including NRG1, ErbB4, GluN2B, and DAAO.14-16 We 
showed a loss of parvalbumin immunoreactivity in response to anti-NMDAR antibody treatment 
(Chapter 4, Figure 2), and this class of interneurons is implicated in the pathophysiology of 
schizophrenia.17-19 Recording from these neurons to see if physiological abnormalities also occur 
in response to the direct loss of NMDAR transmission or the induction of homeostatic plasticity, or 
both, could more strongly link the etiologies of these disorders. Performing EEGs on infused 
animals to measure the power of gamma-frequency firing, which is dependent on PV+ 
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interneuron integrity and commonly disrupted in schizophrenia patients and animal models, is 
another future experiment. 
One of the most compelling questions, and certainly one of utmost clinical importance, is 
the divergent time-course between clearance of anti-neuronal antibodies and amelioration of 
symptoms. Long after antibodies are undetectable in serum or CSF, patients remain functionally 
compromised. It can take up to two years for a full return to work and normal routine, and 
sometimes even years after treatment people are left with cognitive deficiencies. A faithful 
predictor of a good outcome is early intervention.20 However, the persistent neurological problems 
even in the absence of antibody exposure remain mysterious. In culture, receptor levels return to 
baseline within a few days of antibody removal;21,22 similarly, in an animal model, immunoglobulin 
(IgG) clearance and recovery of NMDARs is complete within twelve days of cessation of antibody 
infusion.1   
The various neurotransmitter systems of the central nervous system do not operate in 
isolation, but dynamically modulate each other. The glutamate and dopamine systems, for 
example, are intimately intertwined, and both are major players in psychosis and cognition. Long-
term blockade of NMDARs leads to a decrease of mesocortical dopamine release, but an 
increase of subcortical and mesolimbic dopamine.23 This complex interaction is mediated by 
glutamatergic projections from the prefrontal cortex and hippocampus. Conversely, dopaminergic 
input modulates glutamate neurotransmission. D2 receptors inhibit glutamatergic transmission 
within the striatum, while D1 receptors enhance it. The prefrontal cortex receives dopaminergic 
projections from the ventral tegmental area (VTA), which tend to promote local GABAergic 
inhibition of pyramidal neurons. Thus, a hypoglutamatergic state could lead to decreased 
dopamine release from the VTA, and thus disinhibition within the cortex.24-26  
The exposure to autoantibodies in patients may therefore lead to a cascade of changes, 
both within and between neurotransmitter systems. As antibody titers fall, even though receptor 
density returns to normal, the brain may require additional time to reset to its pre-disease 
baseline.  
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Finally, an animal model of this disease lends itself to exploration of the field of 
neuroimmunology and the brain-immune system interaction. Long thought of as an ‘immune 
privileged’ space, the nervous system is now known to be subject to thorough surveillance by the 
immune system. The characterization of the blood-brain-barrier has shifted from an impenetrable 
gate to a dynamic interface with the immune environment.27-29 In 2008, the majority of anti-
NMDAR encephalitis patients suffered from a paraneoplastic condition provoked by a 
teratoma.30,31 In 2014, less than half of the cases are associated with tumors, but the 
immunological trigger has yet to be elucidated.20 Additionally, for all patient samples examined, 
the epitope is confined to a specific region of the GluN1 subunit of the NMDAR.32 The reason why 
this region is particularly antigenic is unknown.   
Animal models of anti-glutamate receptor encephalitides can be powerful tools for 
understanding the cellular, synaptic and circuit underpinnings of human behavior. In addition to 
these models being clinically important for encephalitis patients, as well as patients with other 
forms of psychosis and cognitive deficits, including schizophrenia, the potential for basic 
neuroscience inquiry is enormous, and just beginning to be explored. 
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Figure 1: Model of patient antibody induced dysfunction and homeostatic plasticity 
(A) In the absence of patient antibodies, glutamate binding to NMDARs and AMPARs leads to an 
influx of ions, including calcium, to depolarize the postsynaptic membrane and activate 
intracellular signaling cascades.  
(B) The postsynaptic neuron also receives inhibitory input from GABAergic synapses. The 
presynaptic inhibitory terminal has vesicles containing the inhibitory neurotransmitter GABA, 
which is released upon terminal depolarization and bind to postsynaptic GABAARs. This allows 
for an influx of chloride ions, which hyperpolarizes the postsynaptic membrane. The combined 
action of these opposing inputs, excitatory and inhibitory, leads to some pattern of action potential 
firing in the postsynaptic neuron, which is also influenced by voltage-gated ion channels within 
the neuronal membrane.  
(C) After patient antibodies bind to NMDARs, they are internalized and lost from the synapse. 
This causes a decrease in both intracellular calcium and postsynaptic depolarization. In 
response, inhibitory synapses are homeostatically downregulated through a reduction in the 
presynaptic vesicular GABA transporter, vGAT, which loads GABA into presynaptic terminals. 
This leads to a reduction in inhibitory currents. At the same time, the intrinsic excitability of the 
postsynaptic neuronal membrane increases, further compensating for the loss of excitatory 
neurotransmission. This is likely mediated through changes in one or more voltage-gated ion 
channels that together shape excitability and firing properties of the membrane. These changes in 
inhibitory synapses and intrinsic excitability are not able to normalize action potential firing and 
lead to a more bursting pattern, which may contribute to seizures and neuropsychiatric symptoms 
in patients. There are several outstanding questions that remain, the loci of which are labeled by 
question marks. First, what is the postsynaptic signal that triggers the cascade of changes 
leading to homeostatic plasticity? In many systems, this has been found to be calcium influx, 
through NMDARs, voltage-gated channels, or intracellular stores. Second, how does this signal 
lead to non-cell autonomous changes in inhibitory synapses? This could be a diffusible 
messenger, such as nitric oxide or endocannabinoids, or could be a retrograde signal through a 
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neurotrophin such as BDNF. Third, once this signal has been transmitted across the synapse, 
does it cause a decrease of vGAT at a transcriptional or translation level? Finally, how is intrinsic 
excitability modified? A variety of voltage-gated conductances are well positioned to enhance 
action potential firing and convert a more tonic firing into bursting. Answers to these questions 
should further clarify the induction and expression of the multitude of homeostatic changes that 
occur upon loss of glutamate transmission in these autoimmune encephalitides.  
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